

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
CYP17A1	<a href="#">10q24.32</a>	17,20-lyase deficiency, isolated	<a href="#">202110</a>	●
CYP17A1	<a href="#">10q24.32</a>	17-alpha-hydroxylase/17,20-lyase deficiency	<a href="#">202110</a>	●
HSD17B10	<a href="#">Xp11.22</a>	17-beta-hydroxysteroid dehydrogenase X deficiency	<a href="#">300438</a>	●
HSD3B2	<a href="#">1p12</a>	3-beta-hydroxysteroid dehydrogenase, type II, deficiency	<a href="#">201810</a>	●
HADH	<a href="#">4q25</a>	3-hydroxyacyl-CoA dehydrogenase deficiency	<a href="#">231530</a>	●
HIBCH	<a href="#">2q32.2</a>	3-hydroxyisobutryl-CoA hydrolase deficiency	<a href="#">250620</a>	●
HIBCH	<a href="#">2q32.2</a>	3-hydroxyisobutryl-CoA hydrolase deficiency	<a href="#">250620</a>	●
AUH	<a href="#">9q22.31</a>	3-methylglutaconic aciduria, type I	<a href="#">250950</a>	●
DNAJC19	<a href="#">3q26.33</a>	3-methylglutaconic aciduria, type V	<a href="#">610198</a>	●
NR5A1	<a href="#">9q33.3</a>	46XY sex reversal 3	<a href="#">612965</a>	●
FGD1	<a href="#">Xp11.22</a>	Aarskog-Scott syndrome	<a href="#">305400</a>	●
EDNRB	<a href="#">13q22.3</a>	ABCD syndrome	<a href="#">600501</a>	●
AAAS	<a href="#">12q13.13</a>	Achalasia-addisonianism-alacrimia syndrome	<a href="#">231550</a>	●
SLC26A2	<a href="#">5q32</a>	Achondrogenesis Ib	<a href="#">600972</a>	●
ACADM	<a href="#">1p31.1</a>	Acyl-CoA dehydrogenase, medium chain, deficiency of	<a href="#">201450</a>	●
ADA	<a href="#">20q13.12</a>	Adenosine deaminase deficiency, partial	<a href="#">102700</a>	●
PKLR	<a href="#">1q22</a>	Adenosine triphosphate, elevated, of erythrocytes	<a href="#">102900</a>	●
CYP11B1	<a href="#">8q24.3</a>	Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency	<a href="#">202010</a>	●
CYP21A2	<a href="#">6p21.33</a>	Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency	<a href="#">201910</a>	●
CYP11A1	<a href="#">15q24.1</a>	Adrenal insufficiency, congenital, with 46XY sex reversal, partial or complete	<a href="#">613743</a>	●
NR5A1	<a href="#">9q33.3</a>	Adrenocortical insufficiency		●
ABCD1	<a href="#">Xq28</a>	Adrenoleukodystrophy	<a href="#">300100</a>	●
ABCD1	<a href="#">Xq28</a>	Adrenomyeloneuropathy, adult	<a href="#">300100</a>	●
FGA	<a href="#">4q31.3</a>	Afibrinogenemia, congenital	<a href="#">202400</a>	●
BTK	<a href="#">Xq22.1</a>	Agammaglobulinemia and isolated hormone deficiency	<a href="#">307200</a>	●
BTK	<a href="#">Xq22.1</a>	Agammaglobulinemia, X-linked 1	<a href="#">300755</a>	●
SLC12A6	<a href="#">15q14</a>	Agenesis of the corpus callosum with peripheral neuropathy	<a href="#">218000</a>	●
TREX1	<a href="#">3p21.31</a>	Aicardi-Goutieres syndrome 1, dominant and recessive	<a href="#">225750</a>	●
RNASEH2B	<a href="#">13q14.3</a>	Aicardi-Goutieres syndrome 2	<a href="#">610181</a>	●
RNASEH2C	<a href="#">11q13.1</a>	Aicardi-Goutieres syndrome 3	<a href="#">610329</a>	●
RNASEH2A	<a href="#">19p13.2</a>	Aicardi-Goutieres syndrome 4	<a href="#">610333</a>	●
SAMHD1	<a href="#">20q11.23</a>	Aicardi-Goutieres syndrome 5	<a href="#">612952</a>	●
CYP11B1	<a href="#">8q24.3</a>	Aldosteronism, glucocorticoid-remediable	<a href="#">103900</a>	●
SLC16A2	<a href="#">Xq13.2</a>	Allan-Herndon-Dudley syndrome	<a href="#">300523</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
RAG1	<a href="#">11p12</a>	Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion..	<a href="#">609889</a>	●
ACAT1	<a href="#">11q22.3</a>	Alpha-methylacetoacetic aciduria	<a href="#">203750</a>	●
AMACR	<a href="#">5p13.2</a>	Alpha-methylacyl-CoA racemase deficiency	<a href="#">614307</a>	●
ATRX	<a href="#">Xq21.1</a>	Alpha-thalassemia myelodysplasia syndrome, somatic	<a href="#">300448</a>	●
ATRX	<a href="#">Xq21.1</a>	Alpha-thalassemia/mental retardation syndrome	<a href="#">301040</a>	●
COL4A5	<a href="#">Xq22.3</a>	Alport syndrome	<a href="#">301050</a>	●
COL4A3	<a href="#">2q36.3</a>	Alport syndrome, autosomal dominant	<a href="#">104200</a>	●
COL4A3	<a href="#">2q36.3</a>	Alport syndrome, autosomal recessive	<a href="#">203780</a>	●
COL4A	<a href="#">2q36.3</a>	Alport syndrome, autosomal recessive	<a href="#">203780</a>	●
ALMS1	<a href="#">2p13.1</a>	Alstrom syndrome	<a href="#">203800</a>	●
LAMB3	<a href="#">1q32.2</a>	Amelogenesis imperfecta, type IA	<a href="#">104530</a>	●
ST3GAL5	<a href="#">2p11.2</a>	Amish infantile epilepsy syndrome	<a href="#">609056</a>	●
FGA	<a href="#">4q31.3</a>	Amyloidosis, familial visceral	<a href="#">105200</a>	●
ALS2	<a href="#">2q33.1</a>	Amyotrophic lateral sclerosis 2, juvenile	<a href="#">205100</a>	●
RMRP	<a href="#">9p13.3</a>	Anauxetic dysplasia	<a href="#">607095</a>	●
AR	<a href="#">Xq12</a>	Androgen insensitivity	<a href="#">300068</a>	●
AR	<a href="#">Xq12</a>	Androgen insensitivity, partial, with or without breast cancer	<a href="#">312300</a>	●
MECP2	<a href="#">Xq28</a>	Angelman syndrome	<a href="#">105830</a>	●
UBE3A	<a href="#">15q11.2</a>	Angelman syndrome	<a href="#">105830</a>	●
UBE3A	<a href="#">15q11.2</a>	Angelman syndrome	<a href="#">105830</a>	●
CDKL5	<a href="#">Xp22.13</a>	Angelman syndrome-like	<a href="#">105830</a>	●
POR	<a href="#">7q11.23</a>	Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis	<a href="#">201750</a>	●
NBN	<a href="#">8q21.3</a>	Aplastic anemia	<a href="#">609135</a>	●
HSD11B2	<a href="#">16q22.1</a>	Apparent mineralocorticoid excess	<a href="#">218030</a>	●
ASL	<a href="#">7q11.21</a>	Argininosuccinic aciduria	<a href="#">207900</a>	●
DDC	<a href="#">7p12.1</a>	Aromatic L-amino acid decarboxylase deficiency	<a href="#">608643</a>	●
DSP	<a href="#">6p24.3</a>	Arrhythmogenic right ventricular dysplasia 8	<a href="#">607450</a>	●
ENPP1	<a href="#">6q23.2</a>	Arterial calcification, generalized, of infancy, 1	<a href="#">208000</a>	●
GLE1	<a href="#">9q34.11</a>	Arthrogryposis, lethal, with anterior horn cell disease	<a href="#">611890</a>	●
VPS33B	<a href="#">15q26.1</a>	Arthrogryposis, renal dysfunction, and cholestasis 1	<a href="#">208085</a>	●
VIPAR	<a href="#">14q24.3</a>	Arthrogryposis, renal dysfunction, and cholestasis 2	<a href="#">613404</a>	●
PRPS1	<a href="#">Xq22.3</a>	Arts syndrome	<a href="#">301835</a>	●
NLGN4X	<a href="#">Xp22.32-p22.31</a>	Asperger syndrome susceptibility, X-linked 2	<a href="#">300497</a>	●
TTPA	<a href="#">8q12.3</a>	Ataxia with isolated vitamin E deficiency	<a href="#">277460</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
APTX	<a href="#">9p21.1</a>	Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia	<a href="#">208920</a>	●
ATM	11q22.3	Ataxia-telangiectasia	<a href="#">208900</a>	●
SLC26A2	<a href="#">5q32</a>	Atelosteogenesis II	<a href="#">256050</a>	●
NLGN4X	<a href="#">Xp22.32-p22.31</a>	Autism susceptibility, X-linked 2	<a href="#">300495</a>	●
MECP2	<a href="#">Xq28</a>	Autism susceptibility, X-linked 3	<a href="#">300496</a>	●
RPL10	<a href="#">Xq28</a>	Autism, susceptibility to, X-linked 5	<a href="#">300847</a>	●
FAS	<a href="#">10q23.31</a>	Autoimmune lymphoproliferative syndrome	<a href="#">601859</a>	●
FAS	<a href="#">10q23.31</a>	Autoimmune lymphoproliferative syndrome, type IA	<a href="#">601859</a>	●
FASLG	<a href="#">1q24.3</a>	Autoimmune lymphoproliferative syndrome, type IB	<a href="#">601859</a>	●
AIRE	<a href="#">21q22.3</a>	Autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia	<a href="#">240300</a>	●
PTEN	<a href="#">10q23.31</a>	Bannayan-Riley-Ruvalcaba syndrome	<a href="#">153480</a>	●
MKS1	<a href="#">17q22</a>	Bardet-Biedl syndrome 13	<a href="#">615990</a>	●
CEP290	<a href="#">12q21.32</a>	Bardet-Biedl syndrome 14	<a href="#">615991</a>	●
TMEM67	<a href="#">8q22.1</a>	Bardet-Biedl syndrome 14, modifier of	<a href="#">209900</a>	●
TAZ	<a href="#">Xq28</a>	Barth syndrome	<a href="#">302060</a>	●
GJB2	<a href="#">13q12.11</a>	Bart-Pumphrey syndrome	<a href="#">149200</a>	●
SLC12A1	<a href="#">15q21.1</a>	Bartter syndrome, type 1	<a href="#">601678</a>	●
KCNJ1	<a href="#">11q24.3</a>	Bartter syndrome, type 2	<a href="#">241200</a>	●
DMD	<a href="#">Xp21.2-p21.1</a>	Becker muscular dystrophy	<a href="#">300376</a>	●
NSD1	<a href="#">5q35.2-q35.3</a>	Beckwith-Wiedemann syndrome	<a href="#">130650</a>	●
COL6A1	<a href="#">21q22.3</a>	Bethlem myopathy	<a href="#">158810</a>	●
COL6A2	<a href="#">21q22.3</a>	Bethlem myopathy	<a href="#">158810</a>	●
COL6A3	<a href="#">2q37.3</a>	Bethlem myopathy	<a href="#">158810</a>	●
AMACR	<a href="#">5p13.2</a>	Bile acid synthesis defect, congenital, 4	<a href="#">214950</a>	●
BTD	<a href="#">3p25.1</a>	Biotinidase deficiency	<a href="#">253260</a>	●
BCS1L	<a href="#">2q35</a>	Bjornstad syndrome	<a href="#">262000</a>	●
BLM	<a href="#">15q26.1</a>	Bloom syndrome	<a href="#">210900</a>	●
COL1A1	<a href="#">17q21.33</a>	Bone mineral density variation QTL, osteoporosis	<a href="#">166710</a>	●
ZNF469	<a href="#">16q24.2</a>	Brittle cornea syndrome 1	<a href="#">229200</a>	●
SCNN1B	<a href="#">16p12.2</a>	Bronchiectasis with or without elevated sweat chloride 1	<a href="#">211400</a>	●
SCNN1A	<a href="#">12p13.31</a>	Bronchiectasis with or without elevated sweat chloride 2	<a href="#">613021</a>	●
SCNN1G	<a href="#">16p12.2</a>	Bronchiectasis with or without elevated sweat chloride 3	<a href="#">613071</a>	●
COL1A1	<a href="#">17q21.33</a>	Caffey disease	<a href="#">114000</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
ASPA	<a href="#">17p13.2</a>	Canavan disease	<a href="#">271900</a>	●
CPS1	<a href="#">2q34</a>	Carbamoylphosphate synthetase I deficiency	<a href="#">237300</a>	●
SCO2	<a href="#">22q13.33</a>	Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1	<a href="#">604377</a>	●
COX15	<a href="#">10q24.2</a>	Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2	<a href="#">615119</a>	●
LMNA	<a href="#">1q22</a>	Cardiomyopathy, dilated, 1A	<a href="#">115200</a>	●
FKTN	<a href="#">9q31.2</a>	Cardiomyopathy, dilated, 1X	<a href="#">611615</a>	●
DMD	<a href="#">Xp21.2-p21.1</a>	Cardiomyopathy, dilated, 3B	<a href="#">302045</a>	●
DSP	<a href="#">6p24.3</a>	Cardiomyopathy, dilated, with woolly hair and keratoderma	<a href="#">605676</a>	●
SLC22A5	<a href="#">5q31.1</a>	Carnitine deficiency, systemic primary	<a href="#">212140</a>	●
SLC25A20	<a href="#">3p21.31</a>	Carnitine-acylcarnitine translocase deficiency	<a href="#">212138</a>	●
RAB23	<a href="#">6p11.2</a>	Carpenter syndrome	<a href="#">201000</a>	●
RMRP	<a href="#">9p13.3</a>	Cartilage-hair hypoplasia	<a href="#">250250</a>	●
NHS	<a href="#">Xp22.13</a>	Cataract 40, X-linked	<a href="#">302200</a>	●
EDN3	<a href="#">20q13.32</a>	Central hypoventilation syndrome, congenital	<a href="#">209880</a>	●
VLDLR	<a href="#">9p24.2</a>	Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1	<a href="#">224050</a>	●
SLC6A8	<a href="#">Xq28</a>	Cerebral creatine deficiency syndrome 1	<a href="#">300352</a>	●
GAMT	<a href="#">19p13.3</a>	Cerebral creatine deficiency syndrome 2	<a href="#">612736</a>	●
SNAP29	<a href="#">22q11.21</a>	Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma	<a href="#">609528</a>	●
ERCC6	<a href="#">10q11.23</a>	Cerebrooculofacioskeletal syndrome 1	<a href="#">214150</a>	●
ERCC2	<a href="#">19q13.32</a>	Cerebrooculofacioskeletal syndrome 2	<a href="#">610756</a>	●
CYP27A1	<a href="#">2q35</a>	Cerebrotendinous xanthomatosis	<a href="#">213700</a>	●
PPT1	<a href="#">1p34.2</a>	Ceroid lipofuscinosis, neuronal, 1	<a href="#">256730</a>	●
CTSD	<a href="#">11p15.5</a>	Ceroid lipofuscinosis, neuronal, 10	<a href="#">610127</a>	●
TPP1	<a href="#">11p15.4</a>	Ceroid lipofuscinosis, neuronal, 2	<a href="#">204500</a>	●
CLN3	<a href="#">16p11.2</a>	Ceroid lipofuscinosis, neuronal, 3	<a href="#">204200</a>	●
CLN5	<a href="#">13q22.3</a>	Ceroid lipofuscinosis, neuronal, 5	<a href="#">256731</a>	●
CLN6	<a href="#">15q23</a>	Ceroid lipofuscinosis, neuronal, 6	<a href="#">601780</a>	●
MFSD8	<a href="#">4q28.2</a>	Ceroid lipofuscinosis, neuronal, 7	<a href="#">610951</a>	●
CLN8	<a href="#">8p23.3</a>	Ceroid lipofuscinosis, neuronal, 8	<a href="#">600143</a>	●
CLN8	<a href="#">8p23.3</a>	Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant	<a href="#">610003</a>	●
CLN6	<a href="#">15q23</a>	Ceroid lipofuscinosis, neuronal, Kufs type, adult onset	<a href="#">204300</a>	●
GDAP1	<a href="#">8q21.11</a>	Charcot-Marie-Tooth disease, axonal, type 2K	<a href="#">607831</a>	●
IGHMBP2	<a href="#">11q13.3</a>	Charcot-Marie-Tooth disease, axonal, type 2S	<a href="#">616155</a>	●
GDAP1	<a href="#">8q21.11</a>	Charcot-Marie-Tooth disease, axonal, with vocal cord paresis	<a href="#">607706</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
MPZ	<a href="#">1q23.3</a>	Charcot-Marie-Tooth disease, dominant intermediate D	<a href="#">607791</a>	●
PLEKHG5	<a href="#">1p36.31</a>	Charcot-Marie-Tooth disease, recessive intermediate C	<a href="#">615376</a>	●
GDAP1	<a href="#">8q21.11</a>	Charcot-Marie-Tooth disease, recessive intermediate, A	<a href="#">608340</a>	●
PMP22	<a href="#">17p12</a>	Charcot-Marie-Tooth disease, type 1A	<a href="#">118220</a>	●
MPZ	<a href="#">1q23.3</a>	Charcot-Marie-Tooth disease, type 1B	<a href="#">118200</a>	●
EGR2	<a href="#">10q21.3</a>	Charcot-Marie-Tooth disease, type 1D	<a href="#">607678</a>	●
PMP22	<a href="#">17p12</a>	Charcot-Marie-Tooth disease, type 1E	<a href="#">118300</a>	●
LMNA	<a href="#">1q22</a>	Charcot-Marie-Tooth disease, type 2B1	<a href="#">605588</a>	●
MPZ	<a href="#">1q23.3</a>	Charcot-Marie-Tooth disease, type 2I	<a href="#">607677</a>	●
MPZ	<a href="#">1q23.3</a>	Charcot-Marie-Tooth disease, type 2J	<a href="#">607736</a>	●
GDAP1	<a href="#">8q21.11</a>	Charcot-Marie-Tooth disease, type 4A	<a href="#">214400</a>	●
PRX	<a href="#">19q13.2</a>	Charcot-Marie-Tooth disease, type 4F	<a href="#">614895</a>	●
FGD4	<a href="#">12p11.21</a>	Charcot-Marie-Tooth disease, type 4H	<a href="#">609311</a>	●
PRPS1	<a href="#">Xq22.3</a>	Charcot-Marie-Tooth disease, X-linked recessive, 5	<a href="#">311070</a>	●
LYST	<a href="#">1q42.3</a>	Chediak-Higashi syndrome	<a href="#">214500</a>	●
TREX1	<a href="#">3p21.31</a>	Chilblain lupus	<a href="#">610448</a>	●
SAMHD1	<a href="#">20q11.23</a>	Chilblain lupus 2	<a href="#">614415</a>	●
ATP8B1	<a href="#">18q21.31</a>	Cholestasis, benign recurrent intrahepatic	<a href="#">243300</a>	●
ABCB11	<a href="#">2q31.1</a>	Cholestasis, benign recurrent intrahepatic, 2	<a href="#">605479</a>	●
ATP8B1	<a href="#">18q21.31</a>	Cholestasis, intrahepatic, of pregnancy, 1	<a href="#">147480</a>	●
ABCB4	<a href="#">7q21.12</a>	Cholestasis, intrahepatic, of pregnancy, 3	<a href="#">614972</a>	●
ATP8B1	<a href="#">18q21.31</a>	Cholestasis, progressive familial intrahepatic 1	<a href="#">211600</a>	●
ABCB11	<a href="#">2q31.1</a>	Cholestasis, progressive familial intrahepatic 2	<a href="#">601847</a>	●
ABCB4	<a href="#">7q21.12</a>	Cholestasis, progressive familial intrahepatic 3	<a href="#">602347</a>	●
ARSE	<a href="#">Xp22.33</a>	Chondrodysplasia punctata, X-linked recessive	<a href="#">302950</a>	●
PTH1R	<a href="#">3p21.31</a>	Chondrodysplasia, Blomstrand type	<a href="#">215045</a>	●
ASS1	<a href="#">9q34.11</a>	Citrullinemia	<a href="#">215700</a>	●
RPGRIP1L	<a href="#">16q12.2</a>	COACH syndrome	<a href="#">216360</a>	●
TMEM67	<a href="#">8q22.1</a>	COACH syndrome	<a href="#">216360</a>	●
ERCC8	<a href="#">5q12.1</a>	Cockayne syndrome, type A	<a href="#">216400</a>	●
ERCC6	<a href="#">10q11.23</a>	Cockayne syndrome, type B	<a href="#">133540</a>	●
COQ2	<a href="#">4q21.23</a>	Coenzyme Q10 deficiency, primary, 1	<a href="#">607426</a>	●
PDSS1	<a href="#">10p12.1</a>	Coenzyme Q10 deficiency, primary, 2	<a href="#">614651</a>	●
PDSS2	<a href="#">6q21</a>	Coenzyme Q10 deficiency, primary, 3	<a href="#">614652</a>	●
ADCK3	<a href="#">1q42.13</a>	Coenzyme Q10 deficiency, primary, 4	<a href="#">612016</a>	●
COQ9	<a href="#">16q21</a>	Coenzyme Q10 deficiency, primary, 5	<a href="#">614654</a>	●
RPS6KA3	<a href="#">Xp22.12</a>	Coffin-Lowry syndrome	<a href="#">303600</a>	●
VPS13B	<a href="#">8q22.2</a>	Cohen syndrome	<a href="#">216550</a>	●
CRLF1	<a href="#">19p13.11</a>	Cold-induced sweating syndrome 1	<a href="#">272430</a>	●
ENPP1	<a href="#">6q23.2</a>	Cole disease	<a href="#">615522</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
RAG1	<a href="#">11p12</a>	Combined cellular and humoral immune defects with granulomas	<a href="#">233650</a>	●
RAG2	<a href="#">11p12</a>	Combined cellular and humoral immune defects with granulomas	<a href="#">233650</a>	●
IL2R	<a href="#">Xq13.1</a>	Combined immunodeficiency, X-linked, moderate	<a href="#">312863</a>	●
GFM1	<a href="#">3q25.32</a>	Combined oxidative phosphorylation deficiency 1	<a href="#">609060</a>	●
MRPS16	<a href="#">10q22.2</a>	Combined oxidative phosphorylation deficiency 2	<a href="#">610498</a>	●
TSFM	<a href="#">12q14.1</a>	Combined oxidative phosphorylation deficiency 3	<a href="#">610505</a>	●
TUFM	<a href="#">16p11.2</a>	Combined oxidative phosphorylation deficiency 4	<a href="#">610678</a>	●
MRPS22	<a href="#">3q23</a>	Combined oxidative phosphorylation deficiency 5	<a href="#">611719</a>	●
PSAP	<a href="#">10q22.1</a>	Combined SAP deficiency	<a href="#">611721</a>	●
NDUFS6	<a href="#">5p15.33</a>	Complex I, mitochondrial respiratory chain, deficiency of	<a href="#">252010</a>	●
PMM2	<a href="#">16p13.2</a>	Congenital disorder of glycosylation, type Ia	<a href="#">212065</a>	●
MPI	<a href="#">15q24.1</a>	Congenital disorder of glycosylation, type Ib	<a href="#">602579</a>	●
ALG6	<a href="#">1p31.3</a>	Congenital disorder of glycosylation, type Ic	<a href="#">603147</a>	●
ALG3	<a href="#">3q27.1</a>	Congenital disorder of glycosylation, type Id	<a href="#">601110</a>	●
DPM1	<a href="#">20q13.13</a>	Congenital disorder of glycosylation, type Ie	<a href="#">608799</a>	●
MPDU1	<a href="#">17p13.1</a>	Congenital disorder of glycosylation, type If	<a href="#">609180</a>	●
ALG12	<a href="#">22q13.33</a>	Congenital disorder of glycosylation, type Ig	<a href="#">607143</a>	●
ALG8	<a href="#">11q14.1</a>	Congenital disorder of glycosylation, type Ih	<a href="#">608104</a>	●
ALG2	<a href="#">9q22.33</a>	Congenital disorder of glycosylation, type Ii	<a href="#">607906</a>	●
MGAT2	<a href="#">14q21.3</a>	Congenital disorder of glycosylation, type IIa	<a href="#">212066</a>	●
MOGS	<a href="#">2p13.1</a>	Congenital disorder of glycosylation, type IIb	<a href="#">606056</a>	●
SLC35C1	<a href="#">11p11.2</a>	Congenital disorder of glycosylation, type IIc	<a href="#">266265</a>	●
B4GALT1	<a href="#">9p21.1</a>	Congenital disorder of glycosylation, type IId	<a href="#">607091</a>	●
COG7	<a href="#">16p12.2</a>	Congenital disorder of glycosylation, type IIe	<a href="#">608779</a>	●
SLC35A1	<a href="#">6q15</a>	Congenital disorder of glycosylation, type IIf	<a href="#">603585</a>	●
COG1	<a href="#">17q25.1</a>	Congenital disorder of glycosylation, type IIg	<a href="#">611209</a>	●
COG8	<a href="#">16q22.1</a>	Congenital disorder of glycosylation, type IIh	<a href="#">611182</a>	●
DPAGT1	<a href="#">11q23.3</a>	Congenital disorder of glycosylation, type Ij	<a href="#">608093</a>	●
ALG1	<a href="#">16p13.3</a>	Congenital disorder of glycosylation, type Ik		●
ALG9	<a href="#">11q23.1</a>	Congenital disorder of glycosylation, type Il	<a href="#">608776</a>	●
DOLK	<a href="#">9q34.11</a>	Congenital disorder of glycosylation, type Im	<a href="#">610768</a>	●
RFT1	<a href="#">3p21.1</a>	Congenital disorder of glycosylation, type In	<a href="#">612015</a>	●
SRD5A3	<a href="#">4q12</a>	Congenital disorder of glycosylation, type Iq	<a href="#">612379</a>	●
ZIC3	<a href="#">Xq26.3</a>	Congenital heart defects, nonsyndromic, 1, X-linked	<a href="#">306955</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
SLC4A11	<a href="#">20p13</a>	Corneal dystrophy, Fuchs endothelial, 4	<a href="#">613268</a>	●
SLC4A11	<a href="#">20p13</a>	Corneal endothelial dystrophy 2, autosomal recessive	<a href="#">217700</a>	●
SLC4A11	<a href="#">20p13</a>	Corneal endothelial dystrophy and perceptive deafness	<a href="#">217400</a>	●
L1CAM	<a href="#">Xq28</a>	Corpus callosum, partial agenesis of	<a href="#">304100</a>	●
PTEN	<a href="#">10q23.31</a>	Cowden syndrome 1	<a href="#">158350</a>	●
CPT1A	<a href="#">11q13.3</a>	CPT deficiency, hepatic, type IA	<a href="#">255120</a>	●
CPT2	<a href="#">1p32.3</a>	CPT deficiency, hepatic, type II	<a href="#">600649</a>	●
CPT2	<a href="#">1p32.3</a>	CPT II deficiency, lethal neonatal	<a href="#">608836</a>	●
EFNB1	<a href="#">Xq13.1</a>	Craniofrontonasal dysplasia	<a href="#">304110</a>	●
L1CAM	<a href="#">Xq28</a>	CRASH syndrome	<a href="#">303350</a>	●
ATR	<a href="#">3q23</a>	Cutaneous telangiectasia and cancer syndrome, familial	<a href="#">614564</a>	●
FBLN5	<a href="#">14q32.12</a>	Cutis laxa, autosomal recessive, type IA	<a href="#">219100</a>	●
EFEMP2	<a href="#">11q13.1</a>	Cutis laxa, autosomal recessive, type IB	<a href="#">614437</a>	●
ATP6V0A2	<a href="#">12q24.31</a>	Cutis laxa, autosomal recessive, type IIA	<a href="#">219200</a>	●
CFTR	<a href="#">7q31.2</a>	Cystic fibrosis	<a href="#">219700</a>	●
CTNS	<a href="#">17p13.2</a>	Cystinosis, atypical nephropathic	<a href="#">219800</a>	●
CTNS	<a href="#">17p13.2</a>	Cystinosis, late-onset juvenile or adolescent nephropathic	<a href="#">219900</a>	●
CTNS	<a href="#">17p13.2</a>	Cystinosis, nephropathic	<a href="#">219800</a>	●
CTNS	<a href="#">17p13.2</a>	Cystinosis, ocular nonnephropathic	<a href="#">219750</a>	●
HSD17B4	<a href="#">5q23.1</a>	D-bifunctional protein deficiency	<a href="#">261515</a>	●
SLC26A2	<a href="#">5q32</a>	De la Chapelle dysplasia	<a href="#">256050</a>	●
ERCC6	<a href="#">10q11.23</a>	De Sanctis-Cacchione syndrome	<a href="#">278800</a>	●
MYO7A	<a href="#">11q13.5</a>	Deafness, autosomal dominant 11	<a href="#">601317</a>	●
GJB2	<a href="#">13q12.11</a>	Deafness, autosomal dominant 3A	<a href="#">601544</a>	●
CDH23	<a href="#">10q22.1</a>	Deafness, autosomal recessive 12	<a href="#">601386</a>	●
USH1C	<a href="#">11p15.1</a>	Deafness, autosomal recessive 18A	<a href="#">602092</a>	●
GJB2	<a href="#">13q12.11</a>	Deafness, autosomal recessive 1A	<a href="#">220290</a>	●
MYO7A	<a href="#">11q13.5</a>	Deafness, autosomal recessive 2	<a href="#">600060</a>	●
PRPS1	<a href="#">Xq22.3</a>	Deafness, X-linked 1	<a href="#">304500</a>	●
TIMM8A	<a href="#">Xq22.1</a>	Deafness, X-linked 1, progressive	<a href="#">300066</a>	●
F9	<a href="#">Xq27.1</a>	Deep venous thrombosis, protection against	<a href="#">300807</a>	●
EGR2	<a href="#">10q21.3</a>	Dejerine-Sottas disease	<a href="#">145900</a>	●
MPZ	<a href="#">1q23.3</a>	Dejerine-Sottas disease	<a href="#">145900</a>	●
PMP22	<a href="#">17p12</a>	Dejerine-Sottas disease	<a href="#">145900</a>	●
PRX	<a href="#">19q13.2</a>	Dejerine-Sottas disease	<a href="#">145900</a>	●
HBB	<a href="#">11p15.4</a>	Delta-beta thalassemia	<a href="#">141749</a>	●
CLCN5	<a href="#">Xp11.23-p11.22</a>	Dent disease	<a href="#">300009</a>	●
OCRL	<a href="#">Xq25-q26</a>	Dent disease 2	<a href="#">300555</a>	●
DHCR24	<a href="#">1p32.3</a>	Desmosterolosis	<a href="#">602398</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
<i>INSR</i>	<a href="#">19p13.2</a>	Diabetes mellitus, insulin-resistant, with acanthosis nigricans	<a href="#">610549</a>	●
<i>ABCC8</i>	<a href="#">11p15.1</a>	Diabetes mellitus, noninsulin-dependent	<a href="#">125853</a>	●
<i>ENPP1</i>	<a href="#">6q23.2</a>	Diabetes mellitus, non-insulin-dependent, susceptibility to	<a href="#">125853</a>	●
<i>ABCC8</i>	<a href="#">11p15.1</a>	Diabetes mellitus, permanent neonatal	<a href="#">606176</a>	●
<i>ABCC8</i>	<a href="#">11p15.1</a>	Diabetes mellitus, transient neonatal 2	<a href="#">610374</a>	●
<i>FOXP3</i>	<a href="#">Xp11.23</a>	Diabetes mellitus, type I, susceptibility to	<a href="#">222100</a>	●
<i>NEUROG3</i>	<a href="#">10q22.1</a>	Diarrhea 4, malabsorptive, congenital	<a href="#">610370</a>	●
<i>SLC26A2</i>	<a href="#">5q32</a>	Diastrophic dysplasia	<a href="#">222600</a>	●
<i>SLC26A2</i>	<a href="#">5q32</a>	Diastrophic dysplasia, broad bone-platyspondylic variant	<a href="#">222600</a>	●
<i>DLD</i>	<a href="#">31.1</a>	Dihydrolipoamide dehydrogenase deficiency	<a href="#">246900</a>	●
<i>DPYD</i>	<a href="#">1p21.3</a>	Dihydropyrimidine dehydrogenase deficiency	<a href="#">274270</a>	●
<i>DSP</i>	<a href="#">6p24.3</a>	Dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis	<a href="#">615821</a>	●
<i>POR</i>	<a href="#">7q11.23</a>	Disordered steroidogenesis due to cytochrome P450 oxidoreductase	<a href="#">613571</a>	●
<i>LRP2</i>	<a href="#">2q31.1</a>	Donnai-Barrow syndrome	<a href="#">222448</a>	●
<i>DMD</i>	<a href="#">Xp21.2-p21.1</a>	Duchenne muscular dystrophy	<a href="#">310200</a>	●
<i>G6PC3</i>	<a href="#">17q21.31</a>	Dursun syndrome	<a href="#">612541</a>	●
<i>IKBKAP</i>	<a href="#">9q31.3</a>	Dysautonomia, familial	<a href="#">223900</a>	●
<i>FGA</i>	<a href="#">4q31.3</a>	Dysfibrinogenemia, congenital	<a href="#">616004</a>	●
<i>DKC1</i>	<a href="#">Xq28</a>	Dyskeratosis congenita, X-linked	<a href="#">305000</a>	●
<i>PLG</i>	<a href="#">6q26</a>	Dysplasminogenemia	<a href="#">217090</a>	●
<i>HSPG2</i>	<a href="#">1p36.12</a>	Dyssegmental dysplasia, Silverman-Handmaker type	<a href="#">224410</a>	●
<i>COL6A3</i>	<a href="#">2q37.3</a>	Dystonia 27	<a href="#">616411</a>	●
<i>COL7A1</i>	<a href="#">3p21.31</a>	EBD inversa	<a href="#">226600</a>	●
<i>COL7A1</i>	<a href="#">3p21.31</a>	EBD, Bart type	<a href="#">132000</a>	●
<i>COL7A1</i>	<a href="#">3p21.31</a>	EBD, localisata variant		●
<i>EDA</i>	<a href="#">Xq13.1</a>	Ectodermal dysplasia 1, hypohidrotic, X-linked	<a href="#">305100</a>	●
<i>IKBKG</i>	<a href="#">Xq28</a>	Ectodermal dysplasia, hypohidrotic, with immune deficiency	<a href="#">300291</a>	●
<i>IKBKG</i>	<a href="#">Xq28</a>	Ectodermal, dysplasia, anhidrotic, lymphedema and immunodeficiency	<a href="#">300301</a>	●
<i>COL1A2</i>	<a href="#">7q21.3</a>	Ehlers-Danlos syndrome, cardiac valvular form	<a href="#">225320</a>	●
<i>COL1A1</i>	<a href="#">17q21.33</a>	Ehlers-Danlos syndrome, classic	<a href="#">130000</a>	●
<i>PLOD1</i>	<a href="#">1p36.22</a>	Ehlers-Danlos syndrome, type VI	<a href="#">225400</a>	●
<i>COL1A1</i>	<a href="#">17q21.33</a>	Ehlers-Danlos syndrome, type VIIA	<a href="#">130060</a>	●
<i>COL1A2</i>	<a href="#">7q21.3</a>	Ehlers-Danlos syndrome, type VIIB	<a href="#">130060</a>	●
<i>PTH1R</i>	<a href="#">3p21.31</a>	Eiken syndrome	<a href="#">600002</a>	●
<i>EVC</i>	<a href="#">4p16.2</a>	Ellis-van Creveld syndrome	<a href="#">225500</a>	●
<i>EVC2</i>	<a href="#">4p16.2</a>	Ellis-van Creveld syndrome	<a href="#">225500</a>	●



# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
LMNA	<a href="#">1q22</a>	Emery-Dreifuss muscular dystrophy 3, AR	<a href="#">181350</a>	●
MECP2	<a href="#">Xq28</a>	Encephalopathy, neonatal severe	<a href="#">300673</a>	●
COL7A1	<a href="#">3p21.31</a>	Epidermolysis bullosa dystrophica, AR	<a href="#">226600</a>	●
ITGB4	<a href="#">17q25.1</a>	Epidermolysis bullosa of hands and feet	<a href="#">131800</a>	●
COL7A1	<a href="#">3p21.31</a>	Epidermolysis bullosa pruriginosa	<a href="#">604129</a>	●
PLEC	<a href="#">8q24.3</a>	Epidermolysis bullosa simplex with pyloric atresia	<a href="#">612138</a>	●
PLEC	<a href="#">8q24.3</a>	Epidermolysis bullosa simplex, Ogná type	<a href="#">131950</a>	●
LAMA3	<a href="#">18q11.2</a>	Epidermolysis bullosa, generalized atrophic benign	<a href="#">226650</a>	●
LAMA3	<a href="#">18q11.2</a>	Epidermolysis bullosa, junctional, Herlitz type	<a href="#">226700</a>	●
LAMB3	<a href="#">1q32.2</a>	Epidermolysis bullosa, junctional, Herlitz type	<a href="#">226700</a>	●
LAMC2	<a href="#">1q25.3</a>	Epidermolysis bullosa, junctional, Herlitz type	<a href="#">226700</a>	●
COL17A1	<a href="#">10q24.3-q25.1</a>	Epidermolysis bullosa, junctional, non-Herlitz type	<a href="#">226650</a>	●
ITGB4	<a href="#">17q25.1</a>	Epidermolysis bullosa, junctional, non-Herlitz type	<a href="#">226650</a>	●
LAMB3	<a href="#">1q32.2</a>	Epidermolysis bullosa, junctional, non-Herlitz type	<a href="#">226650</a>	●
LAMC2	<a href="#">1q25.3</a>	Epidermolysis bullosa, junctional, non-Herlitz type	<a href="#">226650</a>	●
ITGB4	<a href="#">17q25.1</a>	Epidermolysis bullosa, junctional, with pyloric atresia	<a href="#">226730</a>	●
ITGA6	<a href="#">2q31.1</a>	Epidermolysis bullosa, junctional, with pyloric stenosis	<a href="#">226730</a>	●
DSP	<a href="#">6p24.3</a>	Epidermolysis bullosa, lethal acantholytic	<a href="#">609638</a>	●
COL7A1	<a href="#">3p21.31</a>	Epidermolysis bullosa, pretibial	<a href="#">131850</a>	●
RELN	<a href="#">7q22.1</a>	Epilepsy, familial temporal lobe, 7	<a href="#">616436</a>	●
CSTB	<a href="#">21q22.3</a>	Epilepsy, progressive myoclonic 1A (Unverricht and Lundborg)	<a href="#">254800</a>	●
EPM2A	<a href="#">6q24.3</a>	Epilepsy, progressive myoclonic 2A (Lafora)	<a href="#">254780</a>	●
NHLRC1	<a href="#">6p22.3</a>	Epilepsy, progressive myoclonic 2B (Lafora)	<a href="#">254780</a>	●
ALDH7A1	<a href="#">5q23.2</a>	Epilepsy, pyridoxine-dependent	<a href="#">266100</a>	●
ARX	<a href="#">Xp21.3</a>	Epileptic encephalopathy, early infantile, 1	<a href="#">308350</a>	●
ST3GAL3	<a href="#">1p34.1</a>	Epileptic encephalopathy, early infantile, 15	<a href="#">615006</a>	●
CDKL5	<a href="#">Xp22.13</a>	Epileptic encephalopathy, early infantile, 2	<a href="#">300672</a>	●
SLC25A22	<a href="#">11p15.5</a>	Epileptic encephalopathy, early infantile, 3	<a href="#">609304</a>	●
ARHGEF9	<a href="#">Xq11.1-q11.2</a>	Epileptic encephalopathy, early infantile, 8	<a href="#">300607</a>	●
PCDH19	<a href="#">Xq22.1</a>	Epileptic encephalopathy, early infantile, 9	<a href="#">300088</a>	●
SLC26A2	<a href="#">5q32</a>	Epiphyseal dysplasia, multiple, 4	<a href="#">226900</a>	●
HBA1	<a href="#">16p13.3</a>	Thalassemia, alpha-	<a href="#">141750</a>	●
HBB	<a href="#">11p15.4</a>	Thalassemia, beta-	<a href="#">613985</a>	●
CHRNA7	<a href="#">2q37.1</a>	Escobar syndrome	<a href="#">265000</a>	●
ETHE1	<a href="#">19q13.31</a>	Ethylmalonic encephalopathy	<a href="#">602473</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
NDP	<a href="#">Xp11.3</a>	Exudative vitreoretinopathy 2, X-linked	<a href="#">305390</a>	●
GLA	<a href="#">Xq22.1</a>	Fabry disease	<a href="#">301500</a>	●
PTH1R	<a href="#">3p21.31</a>	Failure of tooth eruption, primary	<a href="#">125350</a>	●
MEFV	<a href="#">16p13.3</a>	Familial Mediterranean fever, AR	<a href="#">249100</a>	●
FANCC	<a href="#">9q22.32</a>	Fanconi anemia, complementation group C	<a href="#">227645</a>	●
ERCC4	<a href="#">16p13.12</a>	Fanconi anemia, complementation group Q	<a href="#">610965</a>	●
HADHA	<a href="#">2p23.3</a>	Fatty liver, acute, of pregnancy	<a href="#">609016</a>	●
G6PD	<a href="#">Xq28</a>	Favism	<a href="#">134700</a>	●
GPR98	<a href="#">5q14.3</a>	Febrile seizures, familial, 4	<a href="#">604352</a>	●
RAPSN	<a href="#">11p11.2</a>	Fetal akinesia deformation sequence	<a href="#">208150</a>	●
DOK7	<a href="#">4p16.3</a>	Fetal akinesia deformation sequence	<a href="#">208150</a>	●
CASK	<a href="#">Xp11.4</a>	FG syndrome 4	<a href="#">300422</a>	●
FRAS1	<a href="#">4q21.21</a>	Fraser syndrome	<a href="#">219000</a>	●
FREM2	<a href="#">13q13.3</a>	Fraser syndrome	<a href="#">219000</a>	●
ALDOB	<a href="#">9q31.1</a>	Fructose intolerance	<a href="#">229600</a>	●
FUCA1	<a href="#">1p36.11</a>	Fucosidosis	<a href="#">230000</a>	●
WNT7A	<a href="#">3p25.1</a>	Fuhrmann syndrome	<a href="#">228930</a>	●
GALK1	<a href="#">17q25.1</a>	Galactokinase deficiency with cataracts	<a href="#">230200</a>	●
GALT	<a href="#">9p13.3</a>	Galactosemia	<a href="#">230400</a>	●
ABCB4	<a href="#">7q21.12</a>	Gallbladder disease 1	<a href="#">600803</a>	●
PSAP	<a href="#">10q22.1</a>	Gaucher disease, atypical	<a href="#">610539</a>	●
GBA	<a href="#">1q22</a>	Gaucher disease, perinatal lethal	<a href="#">608013</a>	●
GBA	<a href="#">1q22</a>	Gaucher disease, type I	<a href="#">230800</a>	●
GBA	<a href="#">1q22</a>	Gaucher disease, type II	<a href="#">230900</a>	●
GBA	<a href="#">1q22</a>	Gaucher disease, type III	<a href="#">231000</a>	●
GBA	<a href="#">1q22</a>	Gaucher disease, type IIIC	<a href="#">231005</a>	●
ADAMTSL2	<a href="#">9q34.2</a>	Geleophysic dysplasia 1	<a href="#">231050</a>	●
ETFA	<a href="#">15q24.2-q24.3</a>	Glutaric acidemia IIA	<a href="#">231680</a>	●
ETFB	<a href="#">19q13.41</a>	Glutaric acidemia IIB	<a href="#">231680</a>	●
ETFDH	<a href="#">4q32.1</a>	Glutaric acidemia IIC	<a href="#">231680</a>	●
GCDH	<a href="#">19p13.2</a>	Glutaricaciduria, type I	<a href="#">231670</a>	●
GSS	<a href="#">20q11.22</a>	Glutathione synthetase deficiency	<a href="#">266130</a>	●
AMT	<a href="#">3p21.31</a>	Glycine encephalopathy	<a href="#">605899</a>	●
GCSH	<a href="#">16q23.2</a>	Glycine encephalopathy	<a href="#">605899</a>	●
GLDC	<a href="#">9p24.1</a>	Glycine encephalopathy	<a href="#">605899</a>	●
G6PC	<a href="#">17q21.31</a>	Glycogen storage disease Ia	<a href="#">232200</a>	●
SLC37A4	<a href="#">11q23.3</a>	Glycogen storage disease Ib	<a href="#">232220</a>	●
SLC37A4	<a href="#">11q23.3</a>	Glycogen storage disease Ic	<a href="#">232240</a>	●
GAA	<a href="#">17q25.3</a>	Glycogen storage disease II	<a href="#">232300</a>	●
AGL	<a href="#">1p21.2</a>	Glycogen storage disease IIIa	<a href="#">232400</a>	●
AGL	<a href="#">1p21.2</a>	Glycogen storage disease IIIb	<a href="#">232400</a>	●
GBE1	<a href="#">3p12.2</a>	Glycogen storage disease IV	<a href="#">232500</a>	●
GLB1	<a href="#">3p22.3</a>	GM1-gangliosidosis, type I	<a href="#">230500</a>	●
GLB1	<a href="#">3p22.3</a>	GM1-gangliosidosis, type II	<a href="#">230600</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
GLB1	<a href="#">3p22.3</a>	GM1-gangliosidosis, type III	<a href="#">230650</a>	●
HEXA	<a href="#">15q23</a>	GM2-gangliosidosis, several forms	<a href="#">272800</a>	●
PRPS1	<a href="#">Xq22.3</a>	Gout, PRPS-related	<a href="#">300661</a>	●
BCS1L	<a href="#">2q35</a>	GRACILE syndrome	<a href="#">603358</a>	●
LBR	<a href="#">1q42.12</a>	Greenberg skeletal dysplasia	<a href="#">215140</a>	●
MYO5A	<a href="#">15q21.2</a>	Griscelli syndrome, type 1	<a href="#">214450</a>	●
RAB27A	<a href="#">15q21.3</a>	Griscelli syndrome, type 2	<a href="#">607624</a>	●
HESX1	<a href="#">3p14.3</a>	Growth hormone deficiency with pituitary anomalies	<a href="#">182230</a>	●
PANK2	<a href="#">20p13</a>	HARP syndrome	<a href="#">607236</a>	●
HP	<a href="#">12q24.31</a>	Hawkinsinuria	<a href="#">140350</a>	●
HADHA	<a href="#">2p23.3</a>	HELLP syndrome, maternal, of pregnancy	<a href="#">609016</a>	●
COL4A3	<a href="#">2q36.3</a>	Hematuria, benign familial	<a href="#">141200</a>	●
COL4A	<a href="#">2q36.3</a>	Hematuria, familial benign		●
HFE2	<a href="#">1q21.1</a>	Hemochromatosis, type 2A	<a href="#">602390</a>	●
HAMP	<a href="#">19q13.12</a>	Hemochromatosis, type 2B	<a href="#">613313</a>	●
HBA1	<a href="#">16p13.3</a>	Hemoglobin H disease, nondeletional	<a href="#">613978</a>	●
G6PD	<a href="#">Xq28</a>	Hemolytic anemia due to G6PD deficiency	<a href="#">300908</a>	●
GSS	<a href="#">20q11.22</a>	Hemolytic anemia due to glutathione synthetase deficiency	<a href="#">231900</a>	●
PRF1	<a href="#">10q22.1</a>	Hemophagocytic lymphohistiocytosis, familial, 2	<a href="#">603553</a>	●
UNC13D	<a href="#">17q25.1</a>	Hemophagocytic lymphohistiocytosis, familial, 3	<a href="#">608898</a>	●
STX11	<a href="#">6q24.2</a>	Hemophagocytic lymphohistiocytosis, familial, 4	<a href="#">603552</a>	●
STXBP2	<a href="#">19p13.2</a>	Hemophagocytic lymphohistiocytosis, familial, 5	<a href="#">613101</a>	●
F8	<a href="#">Xq28</a>	Hemophilia A	<a href="#">306700</a>	●
F9	<a href="#">Xq27.1</a>	Hemophilia B	<a href="#">306900</a>	●
SCO1	<a href="#">17p13.1</a>	Hepatic failure, early onset, and neurologic disorder	<a href="#">603644</a>	●
SP110	<a href="#">2q37.1</a>	Hepatic venoocclusive disease with immunodeficiency	<a href="#">235550</a>	●
HBB	<a href="#">11p15.4</a>	Hereditary persistence of fetal hemoglobin	<a href="#">141749</a>	●
AP3B1	<a href="#">5q14.1</a>	Hermansky-Pudlak syndrome 2	<a href="#">608233</a>	●
PLDN	<a href="#">15q21.1</a>	Hermansky-pudlak syndrome 9	<a href="#">614171</a>	●
UNC93B1	<a href="#">11q13.2</a>	Herpes simplex encephalitis, susceptibility to, 1	<a href="#">610551</a>	●
TLR3	<a href="#">4q35.1</a>	Herpes simplex encephalitis, susceptibility to, 2	<a href="#">613002</a>	●
ZIC3	<a href="#">Xq26.3</a>	Heterotaxy, visceral, 1, X-linked	<a href="#">306955</a>	●
HEXA	<a href="#">15q23</a>	Hex A pseudodeficiency	<a href="#">272800</a>	●
TLR3	<a href="#">4q35.1</a>	HIV1 infection, resistance to	<a href="#">609423</a>	●
HMGCL	<a href="#">1p36.11</a>	HMG-CoA lyase deficiency	<a href="#">246450</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
HLCS	<a href="#">21q22.13</a>	Holocarboxylase synthetase deficiency	<a href="#">253270</a>	●
CBS	<a href="#">21q22.3</a>	Homocystinuria, B6-responsive and nonresponsive types	<a href="#">236200</a>	●
LMNA	<a href="#">1q22</a>	Hutchinson-Gilford progeria	<a href="#">176670</a>	●
ANTXR2	<a href="#">4q21.21</a>	Hyaline fibromatosis syndrome	<a href="#">228600</a>	●
ARX	<a href="#">Xp21.3</a>	Hydranencephaly with abnormal genitalia	<a href="#">300215</a>	●
L1CAM	<a href="#">Xq28</a>	Hydrocephalus due to aqueductal stenosis	<a href="#">307000</a>	●
L1CAM	<a href="#">Xq28</a>	Hydrocephalus with congenital idiopathic intestinal pseudoobstruction	<a href="#">307000</a>	●
L1CAM	<a href="#">Xq28</a>	Hydrocephalus with Hirschsprung disease	<a href="#">307000</a>	●
CYP21A2	<a href="#">6p21.33</a>	Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency	<a href="#">201910</a>	●
FH	<a href="#">19p13.2</a>	Hypercholesterolemia, familial	<a href="#">143890</a>	●
MVK	<a href="#">12q24.11</a>	Hyper-IgD syndrome	<a href="#">260920</a>	●
DOCK8	<a href="#">9p24.3</a>	Hyper-IgE recurrent infection syndrome, autosomal recessive	<a href="#">243700</a>	●
ABCC8	<a href="#">11p15.1</a>	Hyperinsulinemic hypoglycemia, familial, 1	<a href="#">256450</a>	●
HADH	<a href="#">4q25</a>	Hyperinsulinemic hypoglycemia, familial, 4	<a href="#">609975</a>	●
INSR	<a href="#">19p13.2</a>	Hyperinsulinemic hypoglycemia, familial, 5	<a href="#">609968</a>	●
SLC25A15	<a href="#">13q14.11</a>	Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome	<a href="#">238970</a>	●
FGA	<a href="#">4q31.3</a>	Hypodysfibrinogenemia, congenital	<a href="#">616004</a>	●
ABCC8	<a href="#">11p15.1</a>	Hypoglycemia of infancy, leucine-sensitive	<a href="#">240800</a>	●
GNRHR	<a href="#">4q13.2</a>	Hypogonadotropic hypogonadism 7 without anosmia	<a href="#">146110</a>	●
CLDN19	<a href="#">1p34.2</a>	Hypomagnesemia 5, renal, with ocular involvement	<a href="#">248190</a>	●
TBCE	<a href="#">1q42.3</a>	Hypoparathyroidism-retardation-dysmorphism syndrome	<a href="#">241410</a>	●
ALPL	<a href="#">1p36.12</a>	Hypophosphatasia, childhood	<a href="#">241510</a>	●
ALPL	<a href="#">1p36.12</a>	Hypophosphatasia, infantile	<a href="#">241500</a>	●
CLCN5	<a href="#">Xp11.23-p11.22</a>	Hypophosphatemic rickets	<a href="#">300554</a>	●
DMP1	<a href="#">4q22.1</a>	Hypophosphatemic rickets, AR	<a href="#">241520</a>	●
ENPP1	<a href="#">6q23.2</a>	Hypophosphatemic rickets, autosomal recessive, 2	<a href="#">613312</a>	●
AR	<a href="#">Xq12</a>	Hypospadias 1, X-linked	<a href="#">300633</a>	●
TSHB	<a href="#">1p13.2</a>	Hypothyroidism, congenital, nongoitrous 4	<a href="#">275100</a>	●
GJB2	<a href="#">13q12.11</a>	Hystrix-like ichthyosis with deafness	<a href="#">602540</a>	●
ABCA12	<a href="#">2q35</a>	Ichthyosis, autosomal recessive 4B (harlequin)	<a href="#">242500</a>	●
TGM1	<a href="#">14q12</a>	Ichthyosis, congenital, autosomal recessive 1	<a href="#">242300</a>	●
CLDN1	<a href="#">3q28</a>	Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis	<a href="#">607626</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
<i>MBTPS2</i>	<a href="#">Xp22.12-p22.11</a>	IFAP syndrome with or without BRESHECK syndrome	<a href="#">308205</a>	●
<i>STIM1</i>	<a href="#">11p15.4</a>	Immunodeficiency 10	<a href="#">612783</a>	●
<i>CD3G</i>	<a href="#">11q23.3</a>	Immunodeficiency 17, CD3 gamma deficient	<a href="#">615607</a>	●
<i>CD3E</i>	<a href="#">11q23.3</a>	Immunodeficiency 18	<a href="#">615615</a>	●
<i>CD3E</i>	<a href="#">11q23.3</a>	Immunodeficiency 18, SCID variant	<a href="#">615615</a>	●
<i>CD3D</i>	<a href="#">11q23.3</a>	Immunodeficiency 19	<a href="#">615617</a>	●
<i>CD247</i>	<a href="#">1q24.2</a>	Immunodeficiency 25	<a href="#">610163</a>	●
<i>IFNGR1</i>	<a href="#">6q23.3</a>	Immunodeficiency 27A, mycobacteriosis, AR	<a href="#">209950</a>	●
<i>IFNGR1</i>	<a href="#">6q23.3</a>	Immunodeficiency 27B, mycobacteriosis, AD	<a href="#">615978</a>	●
<i>IFNGR2</i>	<a href="#">21q22.11</a>	Immunodeficiency 28, mycobacteriosis	<a href="#">614889</a>	●
<i>IL12B</i>	<a href="#">5q33.3</a>	Immunodeficiency 29, mycobacteriosis	<a href="#">614890</a>	●
<i>IL12RB1</i>	<a href="#">19p13.11</a>	Immunodeficiency 30	<a href="#">614891</a>	●
<i>STAT1</i>	<a href="#">2q32.2</a>	Immunodeficiency 31B, mycobacterial and viral infections, autosomal reces.	<a href="#">613796</a>	●
<i>IKBK</i>	<a href="#">Xq28</a>	Immunodeficiency 33	<a href="#">300636</a>	●
<i>TYK2</i>	<a href="#">19p13.2</a>	Immunodeficiency 35	<a href="#">611521</a>	●
<i>ORAI1</i>	<a href="#">12q24.31</a>	Immunodeficiency 9	<a href="#">612782</a>	●
<i>ICOS</i>	<a href="#">2q33.2</a>	Immunodeficiency, common variable, 1	<a href="#">607594</a>	●
<i>CD19</i>	<a href="#">16p11.2</a>	Immunodeficiency, common variable, 3	<a href="#">613493</a>	●
<i>IKBK</i>	<a href="#">Xq28</a>	Immunodeficiency, isolated	<a href="#">300584</a>	●
<i>CD40LG</i>	<a href="#">Xq26.3</a>	Immunodeficiency, X-linked, with hyper-IgM	<a href="#">308230</a>	●
<i>DNMT3B</i>	<a href="#">20q11.21</a>	Immunodeficiency-centromeric instability-facial anomalies syndrome 1	<a href="#">242860</a>	●
<i>FOXP3</i>	<a href="#">Xp11.23</a>	Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked	<a href="#">304790</a>	●
<i>IKBK</i>	<a href="#">Xq28</a>	Incontinentia pigmenti	<a href="#">308300</a>	●
<i>PLA2G6</i>	<a href="#">22q13.1</a>	Infantile neuroaxonal dystrophy 1	<a href="#">256600</a>	●
<i>NTRK1</i>	<a href="#">1q23.1</a>	Insensitivity to pain, congenital, with anhidrosis	<a href="#">256800</a>	●
<i>IL1RN</i>	<a href="#">2q13</a>	Interleukin 1 receptor antagonist deficiency	<a href="#">612852</a>	●
<i>IVD</i>	<a href="#">15q15.1</a>	Isovaleric acidemia	<a href="#">243500</a>	●
<i>TIMM8A</i>	<a href="#">Xq22.1</a>	Jensen syndrome	<a href="#">311150</a>	●
<i>UBR1</i>	<a href="#">15q15.2</a>	Johanson-Blizzard syndrome	<a href="#">243800</a>	●
<i>OFD1</i>	<a href="#">Xp22.2</a>	Joubert syndrome 10	<a href="#">300804</a>	●
<i>NPHP1</i>	<a href="#">2q13</a>	Joubert syndrome 4	<a href="#">609583</a>	●
<i>CEP290</i>	<a href="#">12q21.32</a>	Joubert syndrome 5	<a href="#">610188</a>	●
<i>TMEM67</i>	<a href="#">8q22.1</a>	Joubert syndrome 6	<a href="#">610688</a>	●
<i>RPGRIP1L</i>	<a href="#">16q12.2</a>	Joubert syndrome 7	<a href="#">611560</a>	●
<i>AHI1</i>	<a href="#">6q23.3</a>	Joubert syndrome-3	<a href="#">608629</a>	●
<i>SRD5A3</i>	<a href="#">4q12</a>	Kahrizi syndrome	<a href="#">612713</a>	●
<i>HPRT</i>	<a href="#">Xq26.2-q26.3</a>	KELLEY-SEEGMILLER SYNDROME	<a href="#">300323</a>	●
<i>TBCE</i>	<a href="#">1q42.3</a>	Kenny-Caffey syndrome-1	<a href="#">244460</a>	●
<i>GJB2</i>	<a href="#">13q12.11</a>	Keratitichthyosis-deafness syndrome	<a href="#">148210</a>	●
<i>GJB2</i>	<a href="#">13q12.11</a>	Keratoderma, palmoplantar, with deafness	<a href="#">148350</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
MBTPS2	<a href="#">Xp22.12-p22.11</a>	Keratosis follicularis spinulosa decalvans, X-linked	<a href="#">308800</a>	●
DSP	<a href="#">6p24.3</a>	Keratosis palmoplantaris striata II	<a href="#">612908</a>	●
GALC	<a href="#">14q31.3</a>	Krabbe disease	<a href="#">245200</a>	●
PSAP	<a href="#">10q22.1</a>	Krabbe disease, atypical	<a href="#">611722</a>	●
PDHX	<a href="#">11p13</a>	Lacticacidemia due to PDX1 deficiency	<a href="#">245349</a>	●
LAMA3	<a href="#">18q11.2</a>	Laryngoonychocutaneous syndrome	<a href="#">245660</a>	●
SC5DL	<a href="#">11q23.3</a>	Lathosterolosis	<a href="#">607330</a>	●
HADHA	<a href="#">2p23.3</a>	LCHAD deficiency	<a href="#">609016</a>	●
FH	<a href="#">19p13.2</a>	LDL cholesterol level QTL2	<a href="#">143890</a>	●
CEP290	<a href="#">12q21.32</a>	Leber congenital amaurosis 10	<a href="#">611755</a>	●
BCS1L	<a href="#">2q35</a>	Leigh syndrome	<a href="#">256000</a>	●
NDUFAF	<a href="#">5q12.1</a>	Leigh syndrome	<a href="#">256000</a>	●
NDUFS4	<a href="#">5q11.2</a>	Leigh syndrome	<a href="#">256000</a>	●
NDUFS7	<a href="#">19p13.3</a>	Leigh syndrome	<a href="#">256000</a>	●
COX15	<a href="#">10q24.2</a>	Leigh syndrome due to cytochrome c oxidase deficiency	<a href="#">256000</a>	●
NDUFS3	<a href="#">11p11.2</a>	Leigh syndrome due to mitochondrial complex I deficiency	<a href="#">256000</a>	●
NDUFS8	<a href="#">11q13.2</a>	Leigh syndrome due to mitochondrial complex I deficiency	<a href="#">256000</a>	●
COX10	<a href="#">17p12</a>	Leigh syndrome due to mitochondrial COX4 deficiency	<a href="#">256000</a>	●
SURF1	<a href="#">9q34.2</a>	Leigh syndrome, due to COX deficiency	<a href="#">256000</a>	●
LRPPRC	<a href="#">2p21</a>	Leigh syndrome, French-Canadian type	<a href="#">220111</a>	●
INSR	<a href="#">19p13.2</a>	Leprechaunism	<a href="#">246200</a>	●
HPRT	<a href="#">Xq26.2-q26.3</a>	Lesch-Nyhan syndrome	<a href="#">300322</a>	●
ERBB3	<a href="#">12q13.2</a>	Lethal congenital contractural syndrome 2	<a href="#">607598</a>	●
GLE1	<a href="#">9q34.11</a>	Lethal congenital contracture syndrome 1	<a href="#">253310</a>	●
NBN	<a href="#">8q21.3</a>	Leukemia, acute lymphoblastic	<a href="#">613065</a>	●
NSD1	<a href="#">5q35.2-q35.3</a>	Leukemia, acute myeloid	<a href="#">601626</a>	●
FERMT3	<a href="#">11q13.1</a>	Leukocyte adhesion deficiency, type III	<a href="#">612840</a>	●
GJC2	<a href="#">1q42.13</a>	Leukodystrophy, hypomyelinating, 2	<a href="#">608804</a>	●
FAM126A	<a href="#">7p15.3</a>	Leukodystrophy, hypomyelinating, 5	<a href="#">610532</a>	●
GBA	<a href="#">1q22</a>	Lewy body dementia, susceptibility to	<a href="#">127750</a>	●
LHCGR	<a href="#">2p16.3</a>	Leydig cell adenoma, somatic, with precocious puberty	<a href="#">176410</a>	●
LHCGR	<a href="#">2p16.3</a>	Leydig cell hypoplasia with hypergonadotropic hypogonadism	<a href="#">238320</a>	●
LHCGR	<a href="#">2p16.3</a>	Leydig cell hypoplasia with pseudohermaphroditism	<a href="#">238320</a>	●
PTEN	<a href="#">10q23.31</a>	Lhermitte-Duclos syndrome	<a href="#">158350</a>	●
SCNN1B	<a href="#">16p12.2</a>	Liddle syndrome	<a href="#">177200</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
SCNN1G	<a href="#">16p12.2</a>	Liddle syndrome	<a href="#">177200</a>	●
LIG4	<a href="#">13q33.3</a>	LIG4 syndrome	<a href="#">606593</a>	●
LMNA	<a href="#">1q22</a>	Lipodystrophy, familial partial, 2	<a href="#">151660</a>	●
STAR	<a href="#">8p11.23</a>	Lipoid adrenal hyperplasia	<a href="#">201710</a>	●
RELN	<a href="#">7q22.1</a>	Lissencephaly 2 (Norman-Roberts type)	<a href="#">257320</a>	●
TUBA1A	<a href="#">12q13.12</a>	Lissencephaly 3	<a href="#">611603</a>	●
DCX	<a href="#">Xq23</a>	Lissencephaly, X-linked	<a href="#">300067</a>	●
ARX	<a href="#">Xp21.3</a>	Lissencephaly, X-linked 2	<a href="#">300215</a>	●
OCRL	<a href="#">Xq25-q26</a>	Lowe syndrome	<a href="#">309000</a>	●
MED12	<a href="#">Xq13.1</a>	Lujan-Fryns syndrome	<a href="#">309520</a>	●
LHCGR	<a href="#">2p16.3</a>	Luteinizing hormone resistance, female	<a href="#">238320</a>	●
GJC2	<a href="#">1q42.13</a>	Lymphedema, hereditary, IC	<a href="#">613480</a>	●
PRF1	<a href="#">10q22.1</a>	Lymphoma, non-Hodgkin	<a href="#">605027</a>	●
SH2D1A	<a href="#">Xq25</a>	Lymphoproliferative syndrome, X-linked, 1	<a href="#">308240</a>	●
XIAP	<a href="#">Xq25</a>	Lymphoproliferative syndrome, X-linked, 2	<a href="#">300635</a>	●
PTEN	<a href="#">10q23.31</a>	Macrocephaly/autism syndrome	<a href="#">605309</a>	●
MYD88	<a href="#">3p22.2</a>	Macroglobulinemia, Waldenstrom, somatic	<a href="#">153600</a>	●
ERCC6	<a href="#">10q11.23</a>	Macular degeneration, age-related, susceptibility to 5	<a href="#">613761</a>	●
MFSD8	<a href="#">4q28.2</a>	Macular dystrophy with central cone involvement	<a href="#">616170</a>	●
LMNA	<a href="#">1q22</a>	Malouf syndrome	<a href="#">212112</a>	●
LMNA	<a href="#">1q22</a>	Mandibuloacral dysplasia	<a href="#">248370</a>	●
ZMPSTE24	<a href="#">1p34.2</a>	Mandibuloacral dysplasia with type B lipodystrophy	<a href="#">608612</a>	●
MAN2B1	<a href="#">19p13.2</a>	Mannosidosis, alpha-, types I and II	<a href="#">248500</a>	●
BCKDHA	<a href="#">19q13.2</a>	Maple syrup urine disease, type Ia	<a href="#">248600</a>	●
BCKDHB	<a href="#">6q14.1</a>	Maple syrup urine disease, type Ib	<a href="#">248600</a>	●
DBT	<a href="#">1p21.2</a>	Maple syrup urine disease, type II	<a href="#">248600</a>	●
SIL1	<a href="#">5q31.2</a>	Marinesco-Sjogren syndrome	<a href="#">248800</a>	●
RAB3GAP2	<a href="#">1q41</a>	Martsolf syndrome	<a href="#">212720</a>	●
L1CAM	<a href="#">Xq28</a>	MASA syndrome	<a href="#">303350</a>	●
PYGM	<a href="#">11q13.1</a>	McArdle disease	<a href="#">232600</a>	●
MKS1	<a href="#">17q22</a>	Meckel syndrome 1	<a href="#">249000</a>	●
TMEM67	<a href="#">8q22.1</a>	Meckel syndrome 3	<a href="#">607361</a>	●
CEP290	<a href="#">12q21.32</a>	Meckel syndrome 4	<a href="#">611134</a>	●
RPGRIP1L	<a href="#">16q12.2</a>	Meckel syndrome 5	<a href="#">611561</a>	●
NPHP3	<a href="#">3q22.1</a>	Meckel syndrome 7	<a href="#">267010</a>	●
MLC1	<a href="#">22q13.33</a>	Megalencephalic leukoencephalopathy with subcortical cysts	<a href="#">604004</a>	●
ATP7A	<a href="#">Xq21.1</a>	Menkes disease	<a href="#">309400</a>	●
CASK	<a href="#">Xp11.4</a>	Mental retardation and microcephaly with pontine and cerebellar hypoplasia	<a href="#">300749</a>	●
DOCK8	<a href="#">9p24.3</a>	Mental retardation, autosomal dominant 2	<a href="#">614113</a>	●
PRSS12	<a href="#">4q26</a>	Mental retardation, autosomal recessive 1	<a href="#">249500</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
ST3GAL3	<a href="#">1p34.1</a>	Mental retardation, autosomal recessive 12	<a href="#">611090</a>	●
TRAPPC9	<a href="#">8q24.3</a>	Mental retardation, autosomal recessive 13	<a href="#">613192</a>	●
NSUN2	<a href="#">5p15.31</a>	Mental retardation, autosomal recessive 5	<a href="#">611091</a>	●
TUSC3	<a href="#">8p22</a>	Mental retardation, autosomal recessive 7	<a href="#">611093</a>	●
GRIK2	<a href="#">6q16.3</a>	Mental retardation, autosomal recessive, 6	<a href="#">611092</a>	●
CASK	<a href="#">Xp11.4</a>	Mental retardation, with or without nystagmus	<a href="#">300422</a>	●
NLGN4X	<a href="#">Xp22.31</a>	Mental retardation, X-linked	<a href="#">300495</a>	●
RPS6KA3	<a href="#">Xp22.12</a>	Mental retardation, X-linked 19	<a href="#">300844</a>	●
IL1RAPL1	<a href="#">Xp21.3</a>	Mental retardation, X-linked 21/34	<a href="#">300143</a>	●
ARX	<a href="#">Xp21.3</a>	Mental retardation, X-linked 29 and others	<a href="#">300419</a>	●
PAK3	<a href="#">Xq23</a>	Mental retardation, X-linked 30/47	<a href="#">300558</a>	●
GDI1	<a href="#">Xq28</a>	Mental retardation, X-linked 41	<a href="#">300849</a>	●
ARHGEF6	<a href="#">Xq26.3</a>	Mental retardation, X-linked 46	<a href="#">300436</a>	●
ACSL4	<a href="#">Xq23</a>	Mental retardation, X-linked 63	<a href="#">300387</a>	●
RAB39B	<a href="#">Xq28</a>	Mental retardation, X-linked 72	<a href="#">300271</a>	●
AGTR2	<a href="#">Xq24</a>	Mental retardation, X-linked 88	<a href="#">300852</a>	●
FTSJ1	<a href="#">Xp11.23</a>	Mental retardation, X-linked 9	<a href="#">309549</a>	●
DLG3	<a href="#">Xq13.1</a>	Mental retardation, X-linked 90	<a href="#">300850</a>	●
BRWD3	<a href="#">Xq21.1</a>	Mental retardation, X-linked 93	<a href="#">300659</a>	●
SYP	<a href="#">Xp11.23</a>	Mental retardation, X-linked 96	<a href="#">300802</a>	●
ZNF711	<a href="#">Xq21.1</a>	Mental retardation, X-linked 97	<a href="#">300803</a>	●
HSD17B10	<a href="#">Xp11.22</a>	Mental retardation, X-linked syndromic 10	<a href="#">300220</a>	●
FGD1	<a href="#">Xp11.22</a>	Mental retardation, X-linked syndromic 16	<a href="#">305400</a>	●
AP1S2	<a href="#">Xp22.2</a>	Mental retardation, X-linked syndromic 5	<a href="#">304340</a>	●
SLC9A6	<a href="#">Xq26.3</a>	Mental retardation, X-linked syndromic, Christianson type	<a href="#">300243</a>	●
MECP2	<a href="#">Xq28</a>	Mental retardation, X-linked syndromic, Lubs type	<a href="#">300260</a>	●
UBE2A	<a href="#">Xq24</a>	Mental retardation, X-linked syndromic, Nascimento-type	<a href="#">300860</a>	●
ZDHHC9	<a href="#">Xq26.1</a>	Mental retardation, X-linked syndromic, Raymond type	<a href="#">300799</a>	●
HUWE1	<a href="#">Xp11.22</a>	Mental retardation, X-linked syndromic, Turner type	<a href="#">300706</a>	●
AFF2 (FMR2)	<a href="#">Xq28</a>	Mental retardation, X-linked, FRAXE type	<a href="#">309548</a>	●
SMS	<a href="#">Xp22.11</a>	Mental retardation, X-linked, Snyder-Robinson type	<a href="#">309583</a>	●
MECP2	<a href="#">Xq28</a>	Mental retardation, X-linked, syndromic 13	<a href="#">300055</a>	●
UPF3B	<a href="#">Xq24</a>	Mental retardation, X-linked, syndromic 14	<a href="#">300676</a>	●
CUL4B	<a href="#">Xq24</a>	Mental retardation, X-linked, syndromic 15 (Cabezas type)	<a href="#">300354</a>	●
KDM5C	<a href="#">Xp11.22</a>	Mental retardation, X-linked, syndromic, Claes-Jensen type	<a href="#">300534</a>	●



# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
<i>OPHN1</i>	<a href="#">Xq12</a>	Mental retardation, X-linked, with cerebellar hypoplasia and distinctive facial appearance	<a href="#">300486</a>	●
<i>SOX3</i>	<a href="#">Xq27.1</a>	Mental retardation, X-linked, with isolated growth hormone deficiency	<a href="#">300123</a>	●
<i>ATRX</i>	<a href="#">Xq21.1</a>	Mental retardation-hypotonic facies syndrome, X-linked	<a href="#">309580</a>	●
<i>ARSA</i>	<a href="#">22q13.33</a>	Metachromatic leukodystrophy	<a href="#">250100</a>	●
<i>PSAP</i>	<a href="#">10q22.1</a>	Metachromatic leukodystrophy due to SAP-b deficiency	<a href="#">249900</a>	●
<i>PTH1R</i>	<a href="#">3p21.31</a>	Metaphyseal chondrodysplasia, Murk Jansen type	<a href="#">156400</a>	●
<i>RMRP</i>	<a href="#">9p13.3</a>	Metaphyseal dysplasia without hypotrichosis	<a href="#">250460</a>	●
<i>MMACHC</i>	<a href="#">1p34.1</a>	Methylmalonic aciduria and homocystinuria, cbIC type	<a href="#">277400</a>	●
<i>MUT</i>	<a href="#">6p12.3</a>	Methylmalonic aciduria, mut(0) type	<a href="#">251000</a>	●
<i>MMAA</i>	<a href="#">4q31.21</a>	Methylmalonic aciduria, vitamin B12-responsive	<a href="#">251100</a>	●
<i>MMAB</i>	<a href="#">12q24.11</a>	Methylmalonic aciduria, vitamin B12-responsive, due to defect in synthesis of adenosylcobalamin, cbIB complementation type	<a href="#">251110</a>	●
<i>MVK</i>	<a href="#">12q24.11</a>	Mevalonic aciduria	<a href="#">610377</a>	●
<i>STRA6</i>	<a href="#">15q24.1</a>	Microphthalmia, isolated, with coloboma 8	<a href="#">601186</a>	●
<i>BCOR</i>	<a href="#">Xp11.4</a>	Microphthalmia, syndromic 2	<a href="#">300166</a>	●
<i>STRA6</i>	<a href="#">15q24.1</a>	Microphthalmia, syndromic 9	<a href="#">601186</a>	●
<i>IL1RN</i>	<a href="#">2q13</a>	Microvascular complications of diabetes 4	<a href="#">612628</a>	●
<i>NDUFA7</i>	<a href="#">19p13.3</a>	Mitochondrial Complex 1 Deficiency (MT-C1D)	<a href="#">252010</a>	●
<i>NDUFA1</i>	<a href="#">Xq24</a>	Mitochondrial complex I deficiency	<a href="#">252010</a>	●
<i>NDUFAF4</i>	<a href="#">6q16.1</a>	Mitochondrial complex I deficiency	<a href="#">252010</a>	●
<i>NDUFS3</i>	<a href="#">11p11.2</a>	Mitochondrial complex I deficiency	<a href="#">252010</a>	●
<i>NDUFS4</i>	<a href="#">5q11.2</a>	Mitochondrial complex I deficiency	<a href="#">252010</a>	●
<i>NDUFS5</i>	<a href="#">1p34.3</a>	Mitochondrial complex I deficiency	<a href="#">252010</a>	●
<i>NDUFV1</i>	<a href="#">11q13.2</a>	Mitochondrial complex I deficiency	<a href="#">252010</a>	●
<i>ACAD9</i>	<a href="#">3q21.3</a>	Mitochondrial complex I deficiency due to ACAD9 deficiency	<a href="#">611126</a>	●
<i>BCS1L</i>	<a href="#">2q35</a>	Mitochondrial complex III deficiency, nuclear type 1	<a href="#">124000</a>	●
<i>UQCRB</i>	<a href="#">8q22.1</a>	Mitochondrial complex III deficiency, nuclear type 3	<a href="#">615158</a>	●
<i>UQCRO</i>	<a href="#">5q31.1</a>	Mitochondrial complex III deficiency, nuclear type 4	<a href="#">615159</a>	●
<i>COX10</i>	<a href="#">17p12</a>	Mitochondrial complex IV deficiency	<a href="#">220110</a>	●
<i>COX6B1</i>	<a href="#">19q13.12</a>	Mitochondrial complex IV deficiency	<a href="#">220110</a>	●
<i>FASTKD2</i>	<a href="#">2q33.3</a>	Mitochondrial complex IV deficiency	<a href="#">220110</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
TYMP	<a href="#">22q13.33</a>	Mitochondrial DNA depletion syndrome 1 (MNGIE type)	<a href="#">603041</a>	●
TK2	<a href="#">16q21</a>	Mitochondrial DNA depletion syndrome 2 (myopathic type)	<a href="#">609560</a>	●
DGUOK	<a href="#">2p13.1</a>	Mitochondrial DNA depletion syndrome 3 (hepatocerebral type)	<a href="#">251880</a>	●
POLG	<a href="#">15q26.1</a>	Mitochondrial DNA depletion syndrome 4A (Alpers type)	<a href="#">203700</a>	●
POLG	<a href="#">15q26.1</a>	Mitochondrial DNA depletion syndrome 4B (MNGIE type)	<a href="#">613662</a>	●
SUCLA2	<a href="#">13q14.2</a>	Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria)	<a href="#">612073</a>	●
MPV17	<a href="#">2p23.3</a>	Mitochondrial DNA depletion syndrome 6 (hepatocerebral type)	<a href="#">256810</a>	●
C10orf2	<a href="#">10q24.31</a>	Mitochondrial DNA depletion syndrome 7 (hepatocerebral type)	<a href="#">271245</a>	●
RRM2B	<a href="#">8q22.3</a>	Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy)	<a href="#">612075</a>	●
RRM2B	<a href="#">8q22.3</a>	Mitochondrial DNA depletion syndrome 8B (MNGIE type)	<a href="#">612075</a>	●
SUCLG1	<a href="#">2p11.2</a>	Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria)	<a href="#">245400</a>	●
POLG	<a href="#">15q26.1</a>	Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE)	<a href="#">607459</a>	●
TIMM8A	<a href="#">Xq22.1</a>	Mohr-Tranebjaerg syndrome	<a href="#">304700</a>	●
MOCS1	<a href="#">6p21.2</a>	Molybdenum cofactor deficiency A	<a href="#">252150</a>	●
MOCS2	<a href="#">5q11.2</a>	Molybdenum cofactor deficiency B	<a href="#">252160</a>	●
ZEB2	<a href="#">2q22.3</a>	Mowat-Wilson syndrome	<a href="#">235730</a>	●
GNPTAB	<a href="#">12q23.2</a>	Mucopolidosis II alpha/beta	<a href="#">252500</a>	●
GNPTAB	<a href="#">12q23.2</a>	Mucopolidosis III alpha/beta	<a href="#">252600</a>	●
MCOLN1	<a href="#">19p13.2</a>	Mucopolidosis IV	<a href="#">252650</a>	●
SGSH	<a href="#">17q25.3</a>	Mucopolysaccharidosis type IIIA (Sanfilippo A)	<a href="#">252900</a>	●
IDUA	<a href="#">4p16.3</a>	Mucopolysaccharidosis Ih ( Hurler Syndrome)	<a href="#">607014</a>	●
IDUA	<a href="#">4p16.3</a>	Mucopolysaccharidosis Ih/s ( HURLER-SCHEIE SYNDROME)	<a href="#">607015</a>	●
IDS	<a href="#">Xq28</a>	Mucopolysaccharidosis II	<a href="#">309900</a>	●
IDUA	<a href="#">4p16.3</a>	Mucopolysaccharidosis Is (SCHEIE SYNDROME)	<a href="#">607016</a>	●
NAGLU	<a href="#">17q21.2</a>	Mucopolysaccharidosis type IIIB (Sanfilippo B)	<a href="#">252920</a>	●
HGSNAT	<a href="#">8p11.21</a>	Mucopolysaccharidosis type IIIC (Sanfilippo C)	<a href="#">252930</a>	●
GLB1	<a href="#">3p22.3</a>	Mucopolysaccharidosis type IVB (Morquio)	<a href="#">253010</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
ARSB	<a href="#">5q14.1</a>	Mucopolysaccharidosis type VI (Maroteaux-Lamy)	<a href="#">253200</a>	●
GUSB	<a href="#">7q11.21</a>	Mucopolysaccharidosis VII	<a href="#">253220</a>	●
TRIM37	<a href="#">17q22</a>	Mulibrey nanism	<a href="#">253250</a>	●
CHRNA1	<a href="#">2q31.1</a>	Multiple pterygium syndrome, lethal type	<a href="#">253290</a>	●
CHRND	<a href="#">2q37.1</a>	Multiple pterygium syndrome, lethal type	<a href="#">253290</a>	●
CHRNA1	<a href="#">2q37.1</a>	Multiple pterygium syndrome, lethal type	<a href="#">253290</a>	●
PLEC	<a href="#">8q24.3</a>	Muscular dystrophy with epidermolysis bullosa simplex	<a href="#">226670</a>	●
LMNA	<a href="#">1q22</a>	Muscular dystrophy, congenital	<a href="#">613205</a>	●
LAMA2	<a href="#">6q22.33</a>	Muscular dystrophy, congenital merosin-deficient	<a href="#">607855</a>	●
LAMA2	<a href="#">6q22.33</a>	Muscular dystrophy, congenital, due to partial LAMA2 deficiency	<a href="#">607855</a>	●
LMNA	<a href="#">1q22</a>	Muscular dystrophy, limb-girdle, type 1B	<a href="#">159001</a>	●
PLEC	<a href="#">8q24.3</a>	Muscular dystrophy, limb-girdle, type 2Q	<a href="#">613723</a>	●
SEPN1	<a href="#">1p36.11</a>	Muscular dystrophy, rigid spine, 1	<a href="#">602771</a>	●
POMT1	<a href="#">9q34.13</a>	Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1	<a href="#">236670</a>	●
POMT2	<a href="#">14q24.3</a>	Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2	<a href="#">613150</a>	●
POMGNT1	<a href="#">1p34.1</a>	Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 3	<a href="#">253280</a>	●
FKTN	<a href="#">9q31.2</a>	Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4	<a href="#">253800</a>	●
FKRP	<a href="#">19q13.32</a>	Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5	<a href="#">613153</a>	●
LARGE	<a href="#">22q12.3</a>	Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 6	<a href="#">613154</a>	●
POMT1	<a href="#">9q34.13</a>	Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 1	<a href="#">613155</a>	●
POMT2	<a href="#">14q24.3</a>	Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 2	<a href="#">613156</a>	●
POMGNT1	<a href="#">1p34.1</a>	Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 3	<a href="#">613151</a>	●
LARGE	<a href="#">22q12.3</a>	Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 6	<a href="#">608840</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
<i>FKRP</i>	<a href="#">19q13.32</a>	Muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5	<a href="#">606612</a>	●
<i>FKTN</i>	<a href="#">9q31.2</a>	Muscular dystrophy-dystroglycanopathy (congenital without mental retardation), type B, 4	<a href="#">613152</a>	●
<i>POMT1</i>	<a href="#">9q34.13</a>	Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1	<a href="#">609308</a>	●
<i>POMT2</i>	<a href="#">14q24.3</a>	Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2	<a href="#">613158</a>	●
<i>POMGNT1</i>	<a href="#">1p34.1</a>	Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3	<a href="#">613157</a>	●
<i>FKTN</i>	<a href="#">9q31.2</a>	Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 4	<a href="#">611588</a>	●
<i>FKRP</i>	<a href="#">19q13.32</a>	Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5	<a href="#">607155</a>	●
<i>DOK7</i>	<a href="#">4p16.3</a>	Myasthenic syndrome, congenital, 10	<a href="#">254300</a>	●
<i>RAPSN</i>	<a href="#">11p11.2</a>	Myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency	<a href="#">616326</a>	●
<i>DPAGT1</i>	<a href="#">11q23.3</a>	Myasthenic syndrome, congenital, 13, with tubular aggregates	<a href="#">614750</a>	●
<i>ALG2</i>	<a href="#">9q22.33</a>	Myasthenic syndrome, congenital, 14, with tubular aggregates	<a href="#">616228</a>	●
<i>CHRNA1</i>	<a href="#">2q31.1</a>	Myasthenic syndrome, congenital, 1A, slow-channel	<a href="#">601462</a>	●
<i>CHRNA1</i>	<a href="#">2q31.1</a>	Myasthenic syndrome, congenital, 1B, fast-channel	<a href="#">608930</a>	●
<i>CHRND</i>	<a href="#">2q37.1</a>	Myasthenic syndrome, congenital, 3A, slow-channel	<a href="#">616321</a>	●
<i>CHRND</i>	<a href="#">2q37.1</a>	Myasthenic syndrome, congenital, 3B, fast-channel		●
<i>CHRND</i>	<a href="#">2q37.1</a>	Myasthenic syndrome, congenital, 3C, associated with acetylcholine receptor deficiency	<a href="#">616323</a>	●
<i>MPL</i>	<a href="#">1p34.2</a>	Myelofibrosis with myeloid metaplasia, somatic	<a href="#">254450</a>	●
<i>CPT2</i>	<a href="#">1p32.3</a>	Myopathy due to CPT II deficiency	<a href="#">255110</a>	●
<i>SEPN1</i>	<a href="#">1p36.11</a>	Myopathy, congenital, with fiber-type disproportion	<a href="#">255310</a>	●
<i>STIM1</i>	<a href="#">11p15.4</a>	Myopathy, tubular aggregate, 1	<a href="#">160565</a>	●
<i>ORAI1</i>	<a href="#">12q24.31</a>	Myopathy, tubular aggregate, 2	<a href="#">615883</a>	●
<i>SCO2</i>	<a href="#">22q13.33</a>	Myopia 6	<a href="#">608908</a>	●
<i>COL6A2</i>	<a href="#">21q22.3</a>	Myosclerosis, congenital	<a href="#">255600</a>	●
<i>MTM1</i>	<a href="#">Xq28</a>	Myotubular myopathy, X-linked	<a href="#">310400</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
NAGS	<a href="#">17q21.31</a>	N-acetylglutamate synthase deficiency	<a href="#">237310</a>	●
NHS	<a href="#">Xp22.13</a>	Nance-Horan syndrome	<a href="#">302350</a>	●
NEB	<a href="#">2q23.3</a>	Nemaline myopathy 2, autosomal recessive	<a href="#">256030</a>	●
CLCN5	<a href="#">Xp11.23- p11.22</a>	Nephrolithiasis, type I	<a href="#">310468</a>	●
NPHP1	<a href="#">2q13</a>	Nephronophthisis 1, juvenile	<a href="#">256100</a>	●
TMEM67	<a href="#">8q22.1</a>	Nephronophthisis 11	<a href="#">613550</a>	●
INVS	<a href="#">9q31.1</a>	Nephronophthisis 2, infantile	<a href="#">602088</a>	●
NPHP3	<a href="#">3q22.1</a>	Nephronophthisis 3	<a href="#">604387</a>	●
NPHP4	<a href="#">1p36.31</a>	Nephronophthisis 4	<a href="#">606966</a>	●
NPHS1	<a href="#">19q13.12</a>	Nephrotic syndrome, type 1	<a href="#">256300</a>	●
NPHS2	<a href="#">1q25.2</a>	Nephrotic syndrome, type 2	<a href="#">600995</a>	●
PLCE1	<a href="#">10q23.33</a>	Nephrotic syndrome, type 3	<a href="#">610725</a>	●
LAMB2	<a href="#">3p21.31</a>	Nephrotic syndrome, type 5, with or without ocular abnormalities	<a href="#">614199</a>	●
FOLR1	<a href="#">11q13.4</a>	Neurodegeneration due to cerebral folate transport deficiency	<a href="#">613068</a>	●
PLA2G6	<a href="#">22q13.1</a>	Neurodegeneration with brain iron accumulation 2B	<a href="#">610217</a>	●
IGHMBP2	<a href="#">11q13.3</a>	Neuronopathy, distal hereditary motor, type VI	<a href="#">604320</a>	●
MPZ	<a href="#">1q23.3</a>	Neuropathy, congenital hypomyelinating	<a href="#">605253</a>	●
EGR2	<a href="#">10q21.3</a>	Neuropathy, congenital hypomyelinating, 1	<a href="#">605253</a>	●
PMP22	<a href="#">17p12</a>	Neuropathy, inflammatory demyelinating	<a href="#">139393</a>	●
PMP22	<a href="#">17p12</a>	Neuropathy, recurrent, with pressure palsies	<a href="#">162500</a>	●
HAX1	<a href="#">1q21.3</a>	Neutropenia, severe congenital 3, autosomal recessive	<a href="#">610738</a>	●
G6PC3	<a href="#">17q21.31</a>	Neutropenia, severe congenital 4, autosomal recessive	<a href="#">612541</a>	●
WAS	<a href="#">Xp11.23</a>	Neutropenia, severe congenital, X-linked	<a href="#">300299</a>	●
SMPD1	<a href="#">11p15.4</a>	Niemann-Pick disease, type A	<a href="#">257200</a>	●
SMPD1	<a href="#">11p15.4</a>	Niemann-Pick disease, type B	<a href="#">607616</a>	●
NPC1	<a href="#">18q11.2</a>	Niemann-Pick disease, type C1	<a href="#">257220</a>	●
NPC2	<a href="#">14q24.3</a>	Niemann-pick disease, type C2	<a href="#">607625</a>	●
NPC1	<a href="#">18q11.2</a>	Niemann-Pick disease, type D	<a href="#">257220</a>	●
NBN	<a href="#">8q21.3</a>	Nijmegen breakage syndrome	<a href="#">251260</a>	●
CASK	<a href="#">Xp11.4</a>	Non-Hodgkin lymphoma, somatic	<a href="#">605027</a>	●
NDP	<a href="#">Xp11.3</a>	Norrie disease	<a href="#">310600</a>	●
NXF5	<a href="#">Xq22.1</a>	Nuclear RNA export factor 5	<a href="#">300319</a>	●
ENPP1	<a href="#">6q23.2</a>	Obesity, susceptibility to	<a href="#">601665</a>	●
ATP7A	<a href="#">Xq21.1</a>	Occipital horn syndrome	<a href="#">304150</a>	●
ALPL	<a href="#">1p36.12</a>	Odontohypophosphatasia	<a href="#">146300</a>	●
WNT10A	<a href="#">2q35</a>	Odontoonychodermal dysplasia	<a href="#">257980</a>	●
MED12	<a href="#">Xq13.1</a>	Ohdo syndrome, X-linked	<a href="#">300895</a>	●
MBTPS2	<a href="#">Xp22.12- p22.11</a>	Olmsted syndrome, X-linked	<a href="#">300918</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
<i>DCLRE1C</i>	<a href="#">10p13</a>	Omenn syndrome	<a href="#">603554</a>	●
<i>RAG1</i>	<a href="#">11p12</a>	Omenn syndrome	<a href="#">603554</a>	●
<i>RAG2</i>	<a href="#">11p12</a>	Omenn syndrome	<a href="#">603554</a>	●
<i>MID1</i>	<a href="#">Xp22.2</a>	Opitz GBBB syndrome, type I	<a href="#">300000</a>	●
<i>MED12</i>	<a href="#">Xq13.1</a>	Opitz-Kaveggia syndrome	<a href="#">305450</a>	●
<i>OPA3</i>	<a href="#">19q13.32</a>	Optic atrophy 3 with cataract	<a href="#">165300</a>	●
<i>OTC</i>	<a href="#">Xp11.4</a>	Ornithine transcarbamylase deficiency	<a href="#">311250</a>	●
<i>OFD1</i>	<a href="#">Xp22.2</a>	Orofaciodigital syndrome I	<a href="#">311200</a>	●
<i>COL1A1</i>	<a href="#">17q21.33</a>	Osteogenesis imperfecta, type I	<a href="#">166200</a>	●
<i>COL1A1</i>	<a href="#">17q21.33</a>	Osteogenesis imperfecta, type II	<a href="#">166210</a>	●
<i>COL1A2</i>	<a href="#">7q21.3</a>	Osteogenesis imperfecta, type II	<a href="#">166210</a>	●
<i>COL1A1</i>	<a href="#">17q21.33</a>	Osteogenesis imperfecta, type III	<a href="#">259420</a>	●
<i>COL1A2</i>	<a href="#">7q21.3</a>	Osteogenesis imperfecta, type III	<a href="#">259420</a>	●
<i>COL1A1</i>	<a href="#">17q21.33</a>	Osteogenesis imperfecta, type IV	<a href="#">166220</a>	●
<i>COL1A2</i>	<a href="#">7q21.3</a>	Osteogenesis imperfecta, type IV	<a href="#">166220</a>	●
<i>CRTAP</i>	<a href="#">3p22.3</a>	Osteogenesis imperfecta, type VII	<a href="#">610682</a>	●
<i>LEPRE1</i>	<a href="#">1p34.2</a>	Osteogenesis imperfecta, type VIII	<a href="#">610915</a>	●
<i>CLCN7</i>	<a href="#">16p13.3</a>	Osteopetrosis, autosomal dominant 2	<a href="#">166600</a>	●
<i>TCIRG1</i>	<a href="#">11q13.2</a>	Osteopetrosis, autosomal recessive 1	<a href="#">259700</a>	●
<i>CA2</i>	<a href="#">8q21.2</a>	Osteopetrosis, autosomal recessive 3, with renal tubular acidosis	<a href="#">259730</a>	●
<i>CLCN7</i>	<a href="#">16p13.3</a>	Osteopetrosis, autosomal recessive 4	<a href="#">611490</a>	●
<i>OSTM1</i>	<a href="#">6q21</a>	Osteopetrosis, autosomal recessive 5	<a href="#">259720</a>	●
<i>VDR</i>	<a href="#">12q13.11</a>	Osteoporosis, involutional	<a href="#">166710</a>	●
<i>COL1A2</i>	<a href="#">7q21.3</a>	Osteoporosis, postmenopausal	<a href="#">166710</a>	●
<i>TNFRSF11B</i>	<a href="#">8q24.12</a>	Paget disease of bone 5, juvenile-onset	<a href="#">239000</a>	●
<i>SOX3</i>	<a href="#">Xq27.1</a>	Panhypopituitarism, X-linked	<a href="#">312000</a>	●
<i>PLA2G6</i>	<a href="#">22q13.1</a>	Parkinson disease 14, autosomal recessive	<a href="#">612953</a>	●
<i>ARX</i>	<a href="#">Xp21.3</a>	Partington syndrome	<a href="#">309510</a>	●
<i>LBR</i>	<a href="#">1q42.12</a>	Pelger-Huet anomaly	<a href="#">169400</a>	●
<i>PLP1</i>	<a href="#">Xq22.2</a>	Pelizaeus-Merzbacher disease	<a href="#">312080</a>	●
<i>ACOX1</i>	<a href="#">17q25.1</a>	Peroxisomal acyl-CoA oxidase deficiency	<a href="#">264470</a>	●
<i>PEX13</i>	<a href="#">2p16.1</a>	Peroxisome biogenesis disorder 11 B	<a href="#">614885</a>	●
<i>PEX13</i>	<a href="#">2p16.1</a>	Peroxisome biogenesis disorder 11A (Zellweger)	<a href="#">614883</a>	●
<i>PEX1</i>	<a href="#">7q21.2</a>	Peroxisome biogenesis disorder 1A (Zellweger)	<a href="#">214100</a>	●
<i>PEX1</i>	<a href="#">7q21.2</a>	Peroxisome biogenesis disorder 1B (NALD/IRD)	<a href="#">601539</a>	●
<i>PEX12</i>	<a href="#">17q12</a>	Peroxisome biogenesis disorder 3A (Zellweger)	<a href="#">614859</a>	●
<i>PEX12</i>	<a href="#">17q12</a>	Peroxisome biogenesis disorder 3B	<a href="#">266510</a>	●
<i>PEX10</i>	<a href="#">1p36.32</a>	Peroxisome biogenesis disorder 6A (Zellweger)	<a href="#">614870</a>	●
<i>PEX10</i>	<a href="#">1p36.32</a>	Peroxisome biogenesis disorder 6B	<a href="#">614871</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
PEX26	<a href="#">22q11.21</a>	Peroxisome biogenesis disorder 7A (Zellweger)	<a href="#">614872</a>	●
PEX26	<a href="#">22q11.21</a>	Peroxisome biogenesis disorder 7B	<a href="#">614873</a>	●
PEX5	<a href="#">3q26.33</a>	Peroxisome biogenesis disorder 7B	611058	●
PEX7	<a href="#">6q23.3</a>	Peroxisome biogenesis disorder 9B	<a href="#">614879</a>	●
HSD17B4	<a href="#">5q23.1</a>	Perrault syndrome 1	<a href="#">233400</a>	●
C10orf2	<a href="#">10q24.31</a>	Perrault syndrome 5		●
PAH	<a href="#">12q23.2</a>	Phenylketonuria	<a href="#">261600</a>	●
PRPS1	<a href="#">Xq22.3</a>	Phosphoribosylpyrophosphate synthetase superactivity	<a href="#">300661</a>	●
LAMB2	<a href="#">3p21.31</a>	Pierson syndrome	<a href="#">609049</a>	●
TCF4	<a href="#">18q21.2</a>	Pitt-Hopkins syndrome	<a href="#">610954</a>	●
POU1F1	<a href="#">3p11.2</a>	Pituitary hormone deficiency, combined, 1	<a href="#">613038</a>	●
PROP1	<a href="#">5q35.3</a>	Pituitary hormone deficiency, combined, 2	<a href="#">262600</a>	●
LHX3	<a href="#">9q34.3</a>	Pituitary hormone deficiency, combined, 3	<a href="#">221750</a>	●
HESX1	<a href="#">3p14.3</a>	Pituitary hormone deficiency, combined, 5	<a href="#">182230</a>	●
PLG	<a href="#">6q26</a>	Plasminogen deficiency, type I	<a href="#">217090</a>	●
PKHD1	<a href="#">6p12.3-p12.2</a>	Polycystic kidney and hepatic disease	<a href="#">263200</a>	●
GBE1	<a href="#">3p12.2</a>	Polyglucosan body disease, adult form	<a href="#">263570</a>	●
TSEN54	<a href="#">17q25.1</a>	Pontocerebellar hypoplasia type 2A	<a href="#">277470</a>	●
TSEN54	<a href="#">17q25.1</a>	Pontocerebellar hypoplasia type 4	<a href="#">225753</a>	●
TSEN54	<a href="#">17q25.1</a>	Pontocerebellar hypoplasia type 5	<a href="#">610204</a>	●
MVK	<a href="#">12q24.11</a>	Porokeratosis 3, disseminated superficial actinic	<a href="#">175900</a>	●
UROS	<a href="#">10q26.1-q26.2</a>	Porphyria, congenital erythropoietic	<a href="#">263700</a>	●
LHCGR	<a href="#">2p16.3</a>	Precocious puberty, male	<a href="#">176410</a>	●
NR5A1	<a href="#">9q33.3</a>	Premature ovarian failure 7	<a href="#">612964</a>	●
ALS2	<a href="#">2q33.1</a>	Primary lateral sclerosis, juvenile	<a href="#">606353</a>	●
POLG	<a href="#">15q26.1</a>	Progressive external ophthalmoplegia, autosomal recessive	<a href="#">258450</a>	●
CFP	<a href="#">Xp11.23</a>	Properdin deficiency, X-linked	<a href="#">312060</a>	●
PCCA	<a href="#">13q32.3</a>	Propionicacidemia	<a href="#">606054</a>	●
PCCB	<a href="#">3q22.3</a>	Propionicacidemia	<a href="#">606054</a>	●
CLCN5	<a href="#">Xp11.23-p11.22</a>	Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis	<a href="#">308990</a>	●
ARX	<a href="#">Xp21.3</a>	Proud syndrome	<a href="#">300004</a>	●
HSD17B3	<a href="#">9q22.32</a>	Pseudohermaphroditism, male, with gynecomastia	<a href="#">264300</a>	●
SCNN1A	<a href="#">12p13.31</a>	Pseudohypoaldosteronism, type I	<a href="#">264350</a>	●
SCNN1B	<a href="#">16p12.2</a>	Pseudohypoaldosteronism, type I	<a href="#">264350</a>	●
SCNN1G	<a href="#">16p12.2</a>	Pseudohypoaldosteronism, type I	<a href="#">264350</a>	●
SRD5A2	<a href="#">2p23.1</a>	Pseudovaginal perineoscrotal hypospadias	<a href="#">264600</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
CTSK	<a href="#">1q21.3</a>	Pycnodysostosis	<a href="#">265800</a>	●
MYD88	<a href="#">3p22.2</a>	Pyogenic bacterial infections, recurrent, due to MYD88 deficiency	<a href="#">612260</a>	●
PNPO	<a href="#">17q21.32</a>	Pyridoxamine 5'-phosphate oxidase deficiency	<a href="#">610090</a>	●
PC	<a href="#">11q13.2</a>	Pyruvate carboxylase deficiency	<a href="#">266150</a>	●
PDHA1	<a href="#">Xp22.12</a>	Pyruvate dehydrogenase E1-alpha deficiency	<a href="#">312170</a>	●
PDP1	<a href="#">8q22.1</a>	Pyruvate dehydrogenase phosphatase deficiency	<a href="#">608782</a>	●
PKLR	<a href="#">1q22</a>	Pyruvate kinase deficiency	<a href="#">266200</a>	●
INSR	<a href="#">19p13.2</a>	Rabson-Mendenhall syndrome	<a href="#">262190</a>	●
FAM20C	<a href="#">7p22.3</a>	Raine syndrome	<a href="#">259775</a>	●
NPHP3	<a href="#">3q22.1</a>	Renal-hepatic-pancreatic dysplasia 1	<a href="#">208540</a>	●
PQBP1	<a href="#">Xp11.23</a>	Renpenning syndrome	<a href="#">309500</a>	●
ZMPSTE24	<a href="#">1p34.2</a>	Restrictive dermopathy, lethal	<a href="#">275210</a>	●
LMNA	<a href="#">1q22</a>	Restrictive dermopathy, lethal	<a href="#">275210</a>	●
OFD1	<a href="#">Xp22.2</a>	Retinitis pigmentosa 23	<a href="#">300424</a>	●
USH2A	<a href="#">1q41</a>	Retinitis pigmentosa 39	<a href="#">613809</a>	●
CLRN1	<a href="#">3q25.1</a>	Retinitis pigmentosa 61	<a href="#">614180</a>	●
MECP2	<a href="#">Xq28</a>	Rett syndrome	<a href="#">312750</a>	●
FOXG1	<a href="#">14q12</a>	Rett syndrome, congenital variant	<a href="#">613454</a>	●
MECP2	<a href="#">Xq28</a>	Rett syndrome, preserved speech variant	<a href="#">312750</a>	●
LBR	<a href="#">1q42.12</a>	Reynolds syndrome	<a href="#">613471</a>	●
PEX7	<a href="#">6q23.3</a>	Rhizomelic chondrodysplasia punctata, type 1	<a href="#">215100</a>	●
AGPS	<a href="#">2q31.2</a>	Rhizomelic chondrodysplasia punctata, type 3	<a href="#">600121</a>	●
VDR	<a href="#">12q13.11</a>	Rickets, vitamin D-resistant, type IIA	<a href="#">277440</a>	●
ESCO2	<a href="#">8p21.1</a>	Roberts syndrome	<a href="#">268300</a>	●
MPZ	<a href="#">1q23.3</a>	Roussy-Levy syndrome	<a href="#">180800</a>	●
PMP22	<a href="#">17p12</a>	Roussy-Levy syndrome	<a href="#">180800</a>	●
SLC17A5	<a href="#">6q13</a>	Salla disease	<a href="#">604369</a>	●
HEXB	<a href="#">5q13.3</a>	Sandhoff disease, infantile, juvenile, and adult forms	<a href="#">268800</a>	●
ESCO2	<a href="#">8p21.1</a>	SC phocomelia syndrome	<a href="#">269000</a>	●
SLC35D1	<a href="#">1p31.3</a>	Schneckenbecken dysplasia	<a href="#">269250</a>	●
WNT10A	<a href="#">2q35</a>	Schopf-Schulz-Passarge syndrome	<a href="#">224750</a>	●
HSPG2	<a href="#">1p36.12</a>	Schwartz-Jampel syndrome, type 1	<a href="#">255800</a>	●
JAK3	<a href="#">19p13.11</a>	SCID, autosomal recessive, T-negative/B-positive type	<a href="#">600802</a>	●
ATR	<a href="#">3q23</a>	Seckel syndrome 1	<a href="#">210600</a>	●
TH	<a href="#">11p15.5</a>	Segawa syndrome, recessive	<a href="#">605407</a>	●
NPHP4	<a href="#">1p36.31</a>	Senior-Loken syndrome 4	<a href="#">606996</a>	●
IQCB1	<a href="#">3q13.33</a>	Senior-Loken syndrome 5	<a href="#">609254</a>	●
CEP290	<a href="#">12q21.32</a>	Senior-Loken syndrome 6	<a href="#">610189</a>	●
NPHP1	<a href="#">2q13</a>	Senior-Loken syndrome-1	<a href="#">266900</a>	●
HESX1	<a href="#">3p14.3</a>	Septooptic dysplasia	<a href="#">182230</a>	●



# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
ADA	<a href="#">20q13.12</a>	Severe combined immunodeficiency due to ADA deficiency	<a href="#">102700</a>	●
NHEJ1	<a href="#">2q35</a>	Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation	<a href="#">611291</a>	●
DCLRE1C	<a href="#">10p13</a>	Severe combined immunodeficiency, Athabascan type	<a href="#">602450</a>	●
RAG1	<a href="#">11p12</a>	Severe combined immunodeficiency, B cell-negative	<a href="#">601457</a>	●
RAG2	<a href="#">11p12</a>	Severe combined immunodeficiency, B cell-negative	<a href="#">601457</a>	●
IL2R	<a href="#">Xq13.1</a>	Severe combined immunodeficiency, X-linked	<a href="#">300400</a>	●
IFT80	<a href="#">3q25.33</a>	Short-rib thoracic dysplasia 2 with or without polydactyly	<a href="#">611263</a>	●
DYNC2H1	<a href="#">11q22.3</a>	Short-rib thoracic dysplasia 3 with or without polydactyly	<a href="#">613091</a>	●
SBDS	<a href="#">7q11.21</a>	Shwachman-Bodian-Diamond syndrome	<a href="#">260400</a>	●
SLC17A5	<a href="#">6q13</a>	Sialic acid storage disorder, infantile	<a href="#">269920</a>	●
NEU1	<a href="#">6p21.33</a>	Sialidosis, type I	<a href="#">256550</a>	●
NEU1	<a href="#">6p21.33</a>	Sialidosis, type II	<a href="#">256550</a>	●
HBB	<a href="#">11p15.4</a>	Sickle cell anemia	<a href="#">603903</a>	●
GPC3	<a href="#">Xq26.2</a>	Simpson-Golabi-Behmel syndrome, type 1	<a href="#">312870</a>	●
OFD1	<a href="#">Xp22.2</a>	Simpson-Golabi-Behmel syndrome, type 2	<a href="#">300209</a>	●
ALDH3A2	<a href="#">17p11.2</a>	Sjogren-Larsson syndrome	<a href="#">270200</a>	●
DSP	<a href="#">6p24.3</a>	Skin fragility-woolly hair syndrome	<a href="#">607655</a>	●
DHCR7	<a href="#">11q13.4</a>	Smith-Lemli-Opitz syndrome	<a href="#">270400</a>	●
NSD1	<a href="#">5q35.2-q35.3</a>	Sotos syndrome 1	<a href="#">117550</a>	●
SACS	<a href="#">13q12.12</a>	Spastic ataxia, Charlevoix-Saguenay type	<a href="#">270550</a>	●
ALS2	<a href="#">2q33.1</a>	Spastic paralysis, infantile onset ascending	<a href="#">607225</a>	●
PLP1	<a href="#">Xq22.2</a>	Spastic paraplegia 2, X-linked	<a href="#">312920</a>	●
GJC2	<a href="#">1q42.13</a>	Spastic paraplegia 44, autosomal recessive	<a href="#">613206</a>	●
NR5A1	<a href="#">9q33.3</a>	Spermatogenic failure 8	<a href="#">613957</a>	●
AR	<a href="#">Xq12</a>	Spinal and bulbar muscular atrophy of Kennedy	<a href="#">313200</a>	●
PLEKHG5	<a href="#">1p36.31</a>	Spinal muscular atrophy, distal, autosomal recessive, 4	<a href="#">611067</a>	●
ATP7A	<a href="#">Xq21.1</a>	Spinal muscular atrophy, distal, X-linked 3	<a href="#">300489</a>	●
UBA1	<a href="#">Xp11.23</a>	Spinal muscular atrophy, X-linked 2, infantile	<a href="#">301830</a>	●
SMN1	<a href="#">5q13.2</a>	Spinal muscular atrophy-1	<a href="#">253300</a>	●
SMN1	<a href="#">5q13.2</a>	Spinal muscular atrophy-2	<a href="#">253550</a>	●
SMN1	<a href="#">5q13.2</a>	Spinal muscular atrophy-3	<a href="#">253400</a>	●
SMN1	<a href="#">5q13.2</a>	Spinal muscular atrophy-4	<a href="#">271150</a>	●
TPP1	<a href="#">11p15.4</a>	Spinocerebellar ataxia, autosomal recessive 7	<a href="#">609270</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
<i>DLL3</i>	<a href="#">19q13.2</a>	Spondylocostal dysostosis 1, autosomal recessive	<a href="#">277300</a>	●
<i>FAS</i>	<a href="#">10q23.31</a>	Squamous cell carcinoma, burn scar-related, somatic		●
<i>SHROOM4</i>	<a href="#">Xp11.22</a>	Stocco dos Santos X-linked mental retardation syndrome	<a href="#">300434</a>	●
<i>STIM1</i>	<a href="#">11p15.4</a>	Stormorken syndrome	<a href="#">185070</a>	●
<i>NUP62</i>	<a href="#">19q13.33</a>	Striatonigral degeneration, infantile	<a href="#">271930</a>	●
<i>LIFR</i>	<a href="#">5p13.1</a>	Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome	<a href="#">601559</a>	●
<i>DCX</i>	<a href="#">Xq23</a>	Subcortical laminal heteropia, X-linked	<a href="#">300067</a>	●
<i>ALDH5A1</i>	<a href="#">6p22.3</a>	Succinic semialdehyde dehydrogenase deficiency	<a href="#">271980</a>	●
<i>OXCT1</i>	<a href="#">5p13.1</a>	Succinyl CoA:3-oxoacid CoA transferase deficiency	<a href="#">245050</a>	●
<i>TSPYL1</i>	<a href="#">6q22.1</a>	Sudden infant death with dysgenesis of the testes syndrome	<a href="#">608800</a>	●
<i>SUOX</i>	<a href="#">12q13.2</a>	Sulfite oxidase deficiency	<a href="#">272300</a>	●
<i>SFTPB</i>	<a href="#">2p11.2</a>	Surfactant metabolism dysfunction, pulmonary, 1	<a href="#">265120</a>	●
<i>SFTPC</i>	<a href="#">8p21.3</a>	Surfactant metabolism dysfunction, pulmonary, 2	<a href="#">610913</a>	●
<i>ABCA3</i>	<a href="#">16p13.3</a>	Surfactant metabolism dysfunction, pulmonary, 3	<a href="#">610921</a>	●
<i>TREX1</i>	<a href="#">3p21.31</a>	Systemic lupus erythematosus, susceptibility to	<a href="#">152700</a>	●
<i>HEXA</i>	<a href="#">15q23</a>	Tay-Sachs disease	<a href="#">272800</a>	●
<i>FOXN1</i>	<a href="#">17q11.2</a>	T-cell immunodeficiency, congenital alopecia, and nail dystrophy	<a href="#">601705</a>	●
<i>WNT3</i>	<a href="#">17q21.31</a>	Tetra-amelia syndrome	<a href="#">273395</a>	●
<i>HBA1</i>	<a href="#">16p13.3</a>	Thalassemias, alpha-	<a href="#">604131</a>	●
<i>HBB</i>	<a href="#">11p15.4</a>	Thalassemias, beta-	<a href="#">613985</a>	●
<i>MPL</i>	<a href="#">1p34.2</a>	Thrombocythemia 2	<a href="#">601977</a>	●
<i>MPL</i>	<a href="#">1p34.2</a>	Thrombocytopenia, congenital amegakaryocytic	<a href="#">604498</a>	●
<i>WAS</i>	<a href="#">Xp11.23</a>	Thrombocytopenia, X-linked	<a href="#">313900</a>	●
<i>WAS</i>	<a href="#">Xp11.23</a>	Thrombocytopenia, X-linked, intermittent	<a href="#">313900</a>	●
<i>F9</i>	<a href="#">Xq27.1</a>	Thrombophilia, X-linked, due to factor IX defect	<a href="#">300807</a>	●
<i>CBS</i>	<a href="#">21q22.3</a>	Thrombosis, hyperhomocysteinemic	<a href="#">236200</a>	●
<i>ADAMTS13</i>	<a href="#">9q34.2</a>	Thrombotic thrombocytopenic purpura, familial	<a href="#">274150</a>	●
<i>COL7A1</i>	<a href="#">3p21.31</a>	Toenail dystrophy, isolated	<a href="#">607523</a>	●
<i>WNT10A</i>	<a href="#">2q35</a>	Tooth agenesis, selective, 4	<a href="#">150400</a>	●
<i>EDA</i>	<a href="#">Xq13.1</a>	Tooth agenesis, selective, X-linked 1	<a href="#">313500</a>	●
<i>COL7A1</i>	<a href="#">3p21.31</a>	Transient bullous of the newborn	<a href="#">131705</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
ERCC2	<a href="#">19q13.32</a>	Trichothiodystrophy 1, photosensitive	<a href="#">601675</a>	●
ERCC3	<a href="#">2q14.3</a>	Trichothiodystrophy 2, photosensitive	<a href="#">616390</a>	●
GTF2H5	<a href="#">6q25.3</a>	Trichothiodystrophy 3, photosensitive	<a href="#">616395</a>	●
HADHA	<a href="#">2p23.3</a>	Trifunctional protein deficiency	<a href="#">609015</a>	●
HADHB	<a href="#">2p23.3</a>	Trifunctional protein deficiency	<a href="#">609015</a>	●
FAH	<a href="#">15q25.1</a>	Tyrosinemia, type I	<a href="#">276700</a>	●
TAT	<a href="#">16q22.2</a>	Tyrosinemia, type II	<a href="#">276600</a>	●
HP	<a href="#">12q24.31</a>	Tyrosinemia, type III	<a href="#">276710</a>	●
COL6A1	<a href="#">21q22.3</a>	Ullrich congenital muscular dystrophy	<a href="#">254090</a>	●
COL6A2	<a href="#">21q22.3</a>	Ullrich congenital muscular dystrophy	<a href="#">254090</a>	●
COL6A3	<a href="#">2q37.3</a>	Ullrich congenital muscular dystrophy	<a href="#">254090</a>	●
WNT7A	<a href="#">3p25.1</a>	Ulna and fibula, absence of, with severe limb deficiency	<a href="#">276820</a>	●
MYO7A	<a href="#">11q13.5</a>	Usher syndrome, type 1B	<a href="#">276900</a>	●
USH1C	<a href="#">11p15.1</a>	Usher syndrome, type 1C	<a href="#">276904</a>	●
CDH23	<a href="#">10q22.1</a>	Usher syndrome, type 1D	<a href="#">601067</a>	●
CDH23	<a href="#">10q22.1</a>	Usher syndrome, type 1D/F digenic	<a href="#">601067</a>	●
USH1G	<a href="#">17q25.1</a>	Usher syndrome, type 1G	<a href="#">606943</a>	●
USH2A	<a href="#">1q41</a>	Usher syndrome, type 2A	<a href="#">276901</a>	●
GPR98	<a href="#">5q14.3</a>	Usher syndrome, type 2C	<a href="#">605472</a>	●
GPR98	<a href="#">5q14.3</a>	Usher syndrome, type 2C, GPR98/PDZD7 digenic	<a href="#">605472</a>	●
CLRN1	<a href="#">3q25.1</a>	Usher syndrome, type 3A	<a href="#">276902</a>	●
ERCC6	<a href="#">10q11.23</a>	UV-sensitive syndrome 1	<a href="#">600630</a>	●
ERCC8	<a href="#">5q12.1</a>	UV-sensitive syndrome 2	<a href="#">614621</a>	●
ZIC3	<a href="#">Xq26.3</a>	VACTERL association, X-linked	<a href="#">314390</a>	●
TREX1	<a href="#">3p21.31</a>	Vasculopathy, retinal, with cerebral leukodystrophy	<a href="#">192315</a>	●
PTEN	<a href="#">10q23.31</a>	VATER association with macrocephaly and ventriculomegaly	<a href="#">276950</a>	●
CYP27B1	<a href="#">12q14.1</a>	Vitamin D-dependent rickets, type I	<a href="#">264700</a>	●
ACADL	<a href="#">17p13.1</a>	VLCAD deficiency	<a href="#">201475</a>	●
ACADVL	<a href="#">17p13.1</a>	VLCAD deficiency	<a href="#">201475</a>	●
GJB2	<a href="#">13q12.11</a>	Vohwinkel syndrome	<a href="#">124500</a>	●
EDNRB	<a href="#">13q22.3</a>	Waardenburg syndrome, type 4A	<a href="#">277580</a>	●
EDN3	<a href="#">20q13.32</a>	Waardenburg syndrome, type 4B	<a href="#">613265</a>	●
RAB39B	<a href="#">Xq28</a>	Waisman syndrome	<a href="#">311510</a>	●
RAB3GAP1	<a href="#">2q21.3</a>	Warburg micro syndrome 1	<a href="#">600118</a>	●
RAB3GAP2	<a href="#">1q41</a>	Warburg micro syndrome 2	<a href="#">614225</a>	●
F9	<a href="#">Xq27.1</a>	Warfarin sensitivity	<a href="#">122700</a>	●
EVC	<a href="#">4p16.2</a>	Weyers acrodental dysostosis	<a href="#">193530</a>	●
EVC2	<a href="#">4p16.2</a>	Weyers acrofacial dysostosis	<a href="#">193530</a>	●
GPC3	<a href="#">Xq26.2</a>	Wilms tumor, somatic	<a href="#">194070</a>	●
ATP7B	<a href="#">13q14.3</a>	Wilson disease	<a href="#">277900</a>	●
WAS	<a href="#">Xp11.23</a>	Wiskott-Aldrich syndrome	<a href="#">301000</a>	●

# COMPATIBILITY

## GENETIC TEST

GENE	LOCUS	DISEASE	OMIM	
<i>EIF2AK3</i>	<a href="#">2p11.2</a>	Wolcott-Rallison syndrome	<a href="#">226980</a>	●
<i>ATP6V0A2</i>	<a href="#">12q24.31</a>	Wrinkly skin syndrome	<a href="#">278250</a>	●
<i>XPA</i>	<a href="#">9q22.33</a>	Xeroderma pigmentosum, group A	<a href="#">278700</a>	●
<i>ERCC3</i>	<a href="#">2q14.3</a>	Xeroderma pigmentosum, group B	<a href="#">610651</a>	●
<i>XPC</i>	<a href="#">3p25.1</a>	Xeroderma pigmentosum, group C	<a href="#">278720</a>	●
<i>ERCC2</i>	<a href="#">19q13.32</a>	Xeroderma pigmentosum, group D	<a href="#">278730</a>	●
<i>DDB2</i>	<a href="#">11p11.2</a>	Xeroderma pigmentosum, group E, DDB-negative subtype	<a href="#">278740</a>	●
<i>ERCC4</i>	<a href="#">16p13.12</a>	Xeroderma pigmentosum, group F	<a href="#">278760</a>	●
<i>ERCC5</i>	<a href="#">3q33.1</a>	Xeroderma pigmentosum, group G	<a href="#">278780</a>	●
<i>ERCC5</i>	<a href="#">3q33.1</a>	Xeroderma pigmentosum, group G/Cockayne syndrome	<a href="#">278780</a>	●
<i>ERCC4</i>	<a href="#">16p13.12</a>	Xeroderma pigmentosum, type F/Cockayne syndrome	<a href="#">278760</a>	●
<i>ERCC4</i>	<a href="#">16p13.12</a>	XFE progeroid syndrome	<a href="#">610965</a>	●
<i>ZNF41</i>	<a href="#">Xp11.23</a>	Zinc Finger Protein 41	314995	●
<i>ZNF674</i>	<a href="#">Xp11.3-p11.2</a>	Zinc Finger Protein 674	300573	●